Document:

(1)
CIMYM, Inc.

     

    (2)
CIMAB S.A.

     

    (3)
Innogene Kalbiotech Private Limited

     

    And

     

    (4)
P.T. Kalbe Farma Tbk

     

    Development
and License Agreement

    Relating
to Nimotuzumab (TheraCIM h-R3)

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    Development
and License Agreement

     

    This Agreement dated the 31
day of October, 2005 is made
between:

    

    (1)
 CIMYM, Inc.
(company registration number 12142) ("CIMYM"), a company incorporated in
Canada, whose principal place of business is at 5045 Orbitor Drive, Building II,
Suite 400 Mississauga, Ontario L4W 4Y4; and

    

    (2)
 CIMAB
S.A. (company registration number 107/92) ("CIMAB"), a company
incorporated in Cuba, whose principal place of business is at 206 Street,
No. 1926, e/ I9 y 21, Atabey, Playa, Havana City, Cuba; and

    

    (3)
 Innogene
Kalbiotech Private
Limited (company registration number 200306430D) ("IGK") a company
incorporated in Singapore, whose principal place of business is at
24 Raffles Place, #27-06 Clifford Centre, Singapore 048621);
and

    

    (4)
 P.T. Kalbe Farma,
Tbk, (company registration number J.A. 5/72/23) ("Kalbe"), a
company incorporated in Indonesia, whose principal place of business is at
JI. Let. Jend. Suprapto Kav. 4, Jakarta 10510, P.O. Box 3117 / JKT Jakarta 10002,
Indonesia.

     

    Recitals:

    

    A.  CIMYM is
the exclusive licensee of certain Licensed Patent Rights and certain
Licensed Know-how and other rights relating to marketing and selling
Licensed Product (as defined below) in the Territory (as defined
below).

    

    B.  The
shareholders of CIMYM are YM BioSciences, Inc. and CIMAB.

    

    C.  CIMAB
enters into commercial agreements on behalf of the Center of
Molecular Immunology ("CIM", as defined below). CIM originally developed
Licensed Product (as defined below) and has the facilities to manufacture
Licensed Product. CIMAB is entering into this Agreement principally in
order to assume the manufacturing and supply obligations set out in Clause
5.

    

    D.  IGK
is a subsidiary of Kalbe and Kalbe is an Affiliate (as defined below) of
IGK.

     

    E.  IGK
is a drug development company that wishes to pursue the further development
and commercialisation of Licensed Product for the treatment of cancer in
humans in the Territory and in accordance with the provisions of this
Agreement.

     

    F.  IGK
has demonstrated evidence of economic and financial solvency sufficient to
assume the product development and conduct clinical trials of Licensed
Product in the Territory.

     

    G.  CIMYM
is willing to grant to IGK, and IGK is willing to accept, a license within the
IGK Field and Territory, as defined below, under certain terms and
conditions and in accordance with the provisions of this
Agreement.

     

    It
is agreed as follows:

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    1  Definitions

     

    In this
Agreement, the following words shall have the following meanings:

     

    
      
        
          
            
              
                
                  
                    
                      
                        	
                                Affiliate

                              	 
      	
                                In
      relation to CIMYM or IGK, means any entity or person that controls, is
      controlled by, or is under common control with that Party. For the
      purposes of this definition, "control" shall mean direct or indirect
      beneficial ownership of 50% (or, outside a Party's home territory, such
      lesser percentage as is the maximum, permitted level of foreign
      investment) or more of the share capital, stock or other participating
      interest carrying the right to vote or to distribution of profits of that
      entity or person, as the case may be.

                              
	 	 	 
	
                                Arising
      Intellectual Property

                              	 
      	
                                Any
      and all of the Arising Patents and the Arising
Know-how.

                              
	 	 	 
	
                                Arising
      Know-how

                              	 
      	
                                Technical,
      commercial and all other information generated by any Party or its
      Affiliates or sublicensees under this Agreement that relates to any of the
      Licensed Intellectual Property or the Licensed Product in the Territory,
      including any scientific or regulatory data (including clinical trial data
      generated by IGK), product license applications and approvals, clinical
      trial license applications and approvals, and development and marketing
      plans and activities.

                              
	 	 	 
	
                                Arising
      Patents

                              	 
      	
                                Any
      and all patents and patent applications that may be applied for or
      obtained in respect of any invention(s) made by any Party or its
      Affiliates or sublicensees under this Agreement and which relate to any
      Licensed Intel1ectual Property or the Licensed Product, together with any
      continuations, continuations in part, extensions, reissues, divisions, and
      any patents, supplementary protection certificates and similar rights that
      are based on or derive priority from the foregoing.

                              
	 	 	 
	
                                Calendar
      Quarter

                              	 
      	
                                Each
      three-month period ending on 31st
      March, 30th
      June, 30th
      September and 31st
      December.

                              
	 	 	 
	
                                Calendar
      Year

                              	 
      	
                                A
      year commencing on 1st
      January and ending on 31st
      December (but commencing on the Commencement Date in the first year of
      this Agreement and, in the final year of this Agreement, ending on the
      date of the last sale of Licensed Product under this
      Agreement).

                              
	 	 	 
	
                                CIM

                              	 
      	
                                The
      Center of Molecular Immunology, a scientific research institute based in
      Havana, Cuba.

                              
	 	 	 
	
                                CIMAB’s
      Contract Manufacturer

                              	 
      	
                                Any
      Person that may from time to time be contracted by CIMAB to manufacture
      the Licensed Product, or any component or ingredient thereof in accordance
      with the provisions of this Agreement.

                              
	 	 	 
	
                                CIMYM
      Field and Territory

                              	
                                  

                              	
                                (a)
      outside the Territory, all fields (including the Field); and

                                 

                                (b)
      within the Territory, all fields other than the
  Field.

                              

                      

                    

                  

                

              

            

          

        

      

    

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      
        
          
            
              
                
                  
                    
                      
                        	
                                Claims

                              	 
      	
                                All
      demands, claims and liability (whether criminal or civil, in contract,
      tort or otherwise) for losses, damages, legal costs and other expenses of
      any nature whatsoever and all costs and expenses (including without
      limitation reasonable attorneys fees) incurred in connection
      therewith.

                              
	 	 	 
	
                                Commencement
      Date

                              	 
      	
                                The
      date of execution of this Agreement by the Parties (or, if they sign on
      different dates, the last date of signature of this Agreement by a
      Party).

                              
	 	 	 
	
                                Confidential
      Information

                              	 
      	
                                Means
      any and all trade secrets, technical and non technical and information
      owned by one of the Parties, or by any Affiliates of one of the Parties.
      Confidential Information includes, without limitation, all inventions,
      discoveries, processes, materials, formulae, clinical development plans,
      data, ideas, financial information, legal, corporate, marketing, product,
      research, personnel, customer, supplier and other non-public information,
      in whatever form or media, specifically identified as confidential prior
      to or at the time of its disclosure or disclosed orally and confirmed in
      writing as confidential within thirty (30) days of such oral
      disclosure.

                              
	 	 	 
	
                                Delivered
      Items

                              	 
      	
                                Has
      the meaning given in Clause 4.2.

                              
	 	 	 
	
                                Development
      and Commercialisation
      Plan

                              	 
      	
                                Has
      the meaning given in Clause 3.1.

                              
	 	 	 
	
                                Development
      and Commercialisation
      Plan Report

                              	 
      	
                                The
      report described in Clause 3.4 as amended from time to
    time.

                              
	 	 	 
	
                                Development
      Team Parties

                              	 
      	
                                CIMYM
      and IGK, and "Development Team Party" shall mean either of
      them.

                              
	 	 	 
	
                                Development
      Term

                              	 
      	
                                Means
      the period from the Commencement Date until completion of the development
      of Licensed Product to the point of first commercial sale of a Licensed
      Product in the Territory in accordance with the Development and
      Commercialisation Plan.

                              
	 	 	 
	
                                Diligent
      and Reasonable Efforts

                              	
                                  

                              	
                                Exerting
      such efforts and employing such resources (whether by itself or through
      sub-contractors or sub-licensees) as would normal1y be exerted or employed
      by a reasonable Third Party pharmaceutical company for a product of
      similar market potential at a similar stage of its product life, when
      utilizing sound and reasonable scientific, business and medical practice
      and judgment in order to develop the product in a timely manner and
      maximize the economic return from its
  commercialisation.

                              

                      

                    

                  

                

              

            

          

        

      

    

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      
        
          
            
              
                
                  
                    
                      
                        
                          	
                                  Expiring
      Patents

                                	 
      	
                                  Patents
      or patent applications in the Territory as defined in Clause
      9.1.1.

                                
	 	 	 
	
                                  IGK
      Field and Territory

                                	 
      	
                                  In
      respect of any activity that is licensed to IGK under this Agreement,
      shall mean that the activity must occur both within the Field and within
      the Territory.

                                
	 	 	 
	
                                  Field

                                	 
      	
                                  The
      treatment of cancer in humans.

                                
	 	 	 
	
                                  Gross
      Sales Value

                                	 
      	
                                  Shall
      mean any and all amounts invoiced and received by IGK or any of its
      Affiliates or any of its sublicensees from the sale of the Licensed
      Product to a Third Party in an arm's length transaction (or where the sale
      is not at arm's length, the price that would have been so invoiced and
      received if it had been at arm's length); provided that sales between any
      of IGK and its Affiliates or sublicensees shall not be considered a
      sale for the purposes of this definition unless there is no subsequent
      sale to a Person other than IGK and its Affiliates in an arm's length
      transaction. For the purpose of this definition, a sale shall occur when
      Licensed Product is transferred, shipped, or otherwise distributed to a
      Third Party for valuable consideration that is greater than or equal to
      the Net Sales Value.

                                
	 	 	 
	
                                  Initial
      Development Program

                                	 
      	
                                  A
      program of development to be conducted by IGK in accordance with the
      provisions of the attached Schedule 3 Part A.

                                
	 	 	 
	
                                  Joint
      Development Team

                                	 
      	
                                  A
      committee to be established, and operating, in accordance with the
      provisions of Clause 2.

                                
	 	 	 
	
                                  Know-how

                                	 
      	
                                  The
      Licensed Know-how and the Arising Know-how.

                                
	 	 	 
	
                                  Licensed
      Intellectual Property

                                	 
      	
                                  Any
      and all of the Licensed Patent Rights and the Licensed
      Know-how.

                                
	 	 	 
	
                                  Licensed
      Know-how

                                	 
      	
                                  Technical
      and scientific information in the possession of CIMYM or CIMAB in the
      Field relating to (a) Licensed Product and/or (b) the inventions claimed
      in the Licensed Patent Rights, including the information further described
      in the attached Schedule 2, in each case to the extent that such
      information is relevant, related to, derived from or useful for the
      clinical development, registration, commercialisation, storage, use or
      sale of Licensed Product within the Field in any country within the
      Territory. Licensed Know-how specifically excludes all technology,
      materials, and information related to the manufacture of Licensed
      Product.

                                
	 	 	 
	
                                  Licensed
      Patent Rights

                                	
                                    

                                	
                                  The
      patents and patent applications described in the attached Schedule 1
      subject to the provisions of Schedule 1, together with any continuations,
      continuations in part, extensions, reissues, divisions, and any patents,
      supplementary protection certificates and similar rights that are based on
      or derive priority from the
foregoing.

                                

                        

                      

                    

                  

                

              

            

          

        

      

    

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            	
                                    Licensed
      Product

                                  	 
      	
                                    Any
      product containing the humanised antibody to the EGF receptor, known
      scientifically as h-R3 and which has been given the INN "nimotuzumab" and
      otherwise referred to as TheraCIM h-R3 that is sold or otherwise supplied
      by IGK or its Affiliates and/or which incorporates, or its development
      makes use of, any of the Licensed Know-how or Licensed Patent
      Rights.

                                  
	 	 	 
	
                                    Major
      Countries

                                  	 
      	
                                    Shall
      mean Indonesia, Taiwan, Malaysia, Philippines, South Africa and
      Thailand.

                                  
	 	 	 
	
                                    Milestone
      Receipts

                                  	 
      	
                                    The
      amount of any payment, excluding Value Added Tax, due to CIMYM from IGK as
      described in Clause 7.2.

                                  
	 	 	 
	
                                    Net
      Sales Value

                                  	 
      	
                                    Shall
      mean Gross Sales Value net of (a) normal trade, cash and quantity
      discounts, allowances and credits, actually allowed and taken (including
      credit given for damaged, rejected or returned Licensed Products), (b)
      sales taxes, or other taxes, excluding withholding tax, duties and levies
      of a similar nature actually paid on Licensed Products, (c) freight,
      postage, shipping, insurance and other transportation charges; provided
      always the total deductions pursuant to (a, b, and c) above shall not
      exceed 10% of the Gross Sales Value.

                                  
	 	 	 
	
                                    Orphan
      Drug Status

                                  	 
      	
                                    Refers
      to the process of obtaining Orphan Drug Status in the IGK Field from the
      local drug regulatory authority in any country in the
      Territory.

                                  
	 	 	 
	
                                    Parties

                                  	 
      	
                                    CIMYM,
      CIMAB, Kalbe and IGK, and "Party" shall mean any of
  them.

                                  
	 	 	 
	
                                    Person

                                  	 
      	
                                    Includes
      any individual, firm, company, corporation or other legal
      entity.

                                  
	 	 	 
	
                                    Patents

                                  	 
      	
                                    Any
      and all of the Licensed Patent Rights and the Arising
    Patents.

                                  
	 	 	 
	
                                    Providing
      Parties

                                  	 
      	
                                    Both
      of CIMAB (whether on its own behalf or on behalf of CIM) and CIMYM, and
      "Providing Party" shall mean either of them.

                                  
	 	 	 
	
                                    Regulatory
      Application

                                  	 
      	
                                    Any
      and all applications that are necessary and appropriate to obtain a
      Regulatory Approval including, without limitation, all required documents,
      data and information concerning, filed or required to be filed, otherwise
      submitted by IGK or its Affiliates to a Regulatory
    Authority.

                                  
	 	 	 
	
                                    Regulatory
      Approval

                                  	
                                      

                                  	
                                    Any
      and all approvals, licenses, registrations or authorisations of any
      Regulatory Authority that are necessary for the manufacture, use, storage,
      import, export, transport, marketing, distribution or sale of the Licensed
      Product in any part of the
Territory.

                                  

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      
        
          
            
              
                
                  	
                          Regulatory
      Authority

                        	 
      	
                          The
      equivalents of the US Food and Drug Administration in the
      Territory.

                        
	 	 	 
	
                          Supply
      Agreement

                        	 
      	
                          Any
      agreement between CIMAB, CIMYM and IGK under which CIMAB agrees to
      manufacture and supply IGK with Licensed Product.

                        
	 	 	 
	
                          Territory

                        	 
      	
                          Shall
      mean Thailand, Singapore, Indonesia, Taiwan, Myanmar, Cambodia, Laos,
      Brunei, Philippines, Malaysia, African Republic of the Congo, Nigeria and
      South Africa.

                        
	 	 	 
	
                          TheraCIM
      h-R3

                        	 
      	
                          A
      humanised antibody to the EGF receptor, known scientifically as h-R3 and
      which has been given the INN "nimotuzumab".

                        
	 	 	 
	
                          Third
      Party

                        	 
      	
                          A
      Person other than one of the Parties.

                        
	 	 	 
	
                          Valid
      Claim

                        	
                            

                        	
                          A
      claim of a patent or patent application that has not expired or been held
      invalid or unenforceable by a court of competent jurisdiction in a final
      and non-appealable
judgment.

                        

                

              

            

          

        

      

    

     

    2  Joint
Development Team

    

    2.1  Formation. Within thirty (30)
days after the Commencement Date, the Development Team Parties shall
establish a Joint Development Team, by each Development Team
Party designating its initial members to serve on the Joint Development
Team and notifying the other Development Team Party of its dates of
availability for the first meeting of the Joint Development Team. The
purpose of the Joint Development Team shall be to oversee the development
of Licensed Product for purposes of commercialisation in the IGK Field
and Territory. The Joint Development Team shall consist of not more than
three (3) representatives designated by each Development Team Party. Each
representative shall have relevant and appropriate expertise in order to
oversee the development of the Licensed Product.
If a representative of a Development Team Party is unable to attend a meeting of
the Joint Development Team, such Development Team Party may designate an
alternate to attend such meeting. In addition, each Development Team Party
may, at its discretion, invite a reasonable number of other employees,
consultants or scientific advisors to attend the meetings of the Joint
Development Team, provided that such invitees are bound by appropriate
confidentiality obligations. Each Development Team Party may change one or
all of its representatives to the Joint Development Team at any time upon
notice to the other Development Team Party.

    

    2.2
 Meetings. The
Joint Development Team shall meet every six months in person or
by teleconference and at such other times as the Parties may agree. The
first meeting of the Joint Development Team shall be held as soon as
reasonably practicable, but in no event later than 60 days after the
Commencement Date. Meetings shall be held at such place or places as
are mutually agreed or by teleconference or videoconference; provided,
however, that there shall be at least one face-to-face meeting per calendar
year.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    2.3  Responsibilities. The Joint
Development Team shall:

    

    (a)
Elaborate the Development and Commercialisation Plan in accordance with
Clause 3.1

    

    (b)
review and unanimously approve (or, if the members of the Joint Development
Team are unable to reach unanimous agreement, recommend to the Parties) the
overall development strategy for Licensed Product in the IGK Field and Territory
(including, without limitation, setting criteria for progression of
Licensed Product to the next stage of development under the Development and
Commercialisation Plan);

    

    (c)
review and recommend to the Parties modifications to the Development
and Commercialisation Plan (including the resources to be allocated and the
timelines contained in the Development and Commercialisation Plan);

    

    (d)
facilitate the transfer of Know-How and other information between the Parties
for purposes of conducting the Development and Commercialisation
Plan;

    

    (e)
regularly assess the progress of IGK in its conduct of the Development
and Commercialisation Plan; and

    

    (f)
perform such other activities as are contemplated under this Clause 2. For the
avoidance of doubt the Joint Development Team shall not have any role or
responsibility in relation to determining whether IGK has complied with its
obligations to CIMYM under this Agreement.

    

    2.4
 Disputes. If
agreement cannot be reached within the Joint Development Team, IGK
shall have the right to make the final determination concerning the
resolution of the disagreement. Notwithstanding the foregoing, in the case
of a material disagreement, prior to invoking its rights under this Clause
2.4, IGK agrees to have its chief executive contact the chief executive of
CIMYM for the purpose of discussing the disagreement and attempting to
reach a consensus. It shall be the goal of the chief executives to reach a
consensus within five (5) days of the date on which contact is initiated by
the chief executive of Kalbe, it being understood that (i) in the event of
an extraordinary circumstance requiring a faster resolution (e.g., a safety
issue or extraneous timing issue), IGK shall have the right to make the
final determination prior to the end of such five (5) day period if a
consensus has not been reached by the required time for resolution and (ii)
in the event that a consensus has not been reached within ten (10) days of
the date on which contact is initiated by the chief executive officer of IGK,
IGK shall have the right to make the final determination. For the avoidance of
doubt, IGK shall not have any right, under this clause, to determine
whether it has complied with its obligations to CIMYM under this
Agreement.

    

    3  Development
and Commercialisation

    

    3.1
 Development and
Commercialisation Plan.

    

    3.1.1
 Within 90 days of the Commencement Date, the Joint Development Team shall
prepare a written plan ("Development and Commercialisation Plan") that
expands upon the initial development plan sec out in Schedule 3 and will
describe, and provide a time line for:

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    (a) all
development activities for the Licensed Product in the IGK Field and
Territory, addressing each phase of development and the budget for
completion of such activities, and providing detailed information on the
activities to be conducted in the next 12-month period.

    

    (b)
intellectual property protection strategy, including applying for Orphan Drug
Status,

    patents
and supplementary protection certificates;

    

    (c)
clinical and registration strategy, with a view to expediting Regulatory
Approval; and

    

    (d)
commercialisation strategy.

    

    The Joint
Development Team shall update the Development and Commercialisation Plan on a
regular basis and at least annually.

    

    3.2  Development and Commercialisation
Activities. IGK shall be responsible for the development and
commercialisation (in accordance with the Development and Commercialisation
Plan) of the Licensed Product in the IGK Field and Territory.
Such development and commercialisation shall be carried out under the
oversight and management of the Joint Development Team and in accordance with
the provisions of this Agreement.

    

    3.3
 Development and
Commercialisation Costs. IGK shall bear all costs associated with
the development and commercialisation of Licensed Product in the IGK Field
and Territory, including costs incurred in the preparation and execution of
the Development and Commercialisation
Plan. If any Providing Party agrees with IGK to conduct work as part of the
Development and Commercialisation Plan (which may include advice given to the
Joint Development
Team), the Providing Party's costs of conducting such work shall be borne by
IGK, with
the time costs of the Providing Party's representatives being charged to IGK on
a daily rate basis. The Providing Party's daily rate for its representatives'
work referred to in the previous sentence shall be agreed between the Providing
Party and IGK or, if they are unable to agree, the rate shall be $1,000 (one
thousand US dollars) per day plus any reasonable out-of-pocket expenses and
external costs associated with such work.

    

    3.4
 Reporting. Without prejudice to
the generality of IGK's obligations under Clauses 8.1 and 9.2, IGK shall
provide a report ("Development and Commercialisation Report") to CIMYM at
least once per annum. In addition, IGK shall provide to CIMYM a quarterly,
written status update on all clinical, development and commercial
activities being undertaken, and from time to time upon request, showing
all past, current and projected activities taken or to be taken by IGK to
bring Licensed Product to market and maximise the sale of Licensed Product
in the IGK Field and Territory, and including details of all Arising
Intellectual Property. CIMYM's receipt or approval or non-approval of any
such report shall not be taken to waive or qualify IGK's obligations under
Clause 8.1 or otherwise under this Agreement.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    3.5
 Exchange of Data.
It is CIMYM's intention to grant sub-licenses to commercialise Licensed Product
in the CIMYM Field and Territory and to facilitate the expeditious development
and commercialisation of the Licensed Product in the IGK Field and
Territory. Accordingly,
each of the Parties, or CIMYM's sub-licensee(s), may generate data in relation
to Licensed Product or Licensed Products that is useful to the other Parties in
connection with their development or commercialisation of Licensed
Products. To facilitate such commercialisation, each Party shall disclose and
provide to the other Parties all Arising, technical and clinical trial
information (including case report forms and source documentation) and all
notices and other correspondence between IGK and its Affiliates and any
Regulatory Authority on a quarterly basis in accordance with the provisions
of Clause 3.4. In addition, each Party shall use commercially reasonable efforts
to ensure that their sub-licensee(s) of Licensed Product disclose and
provide to other Party and CIMAB technical and clinical data (including
clinical trial information, case report forms and source documentation) in
respect of Licensed Product that is generated by such sub-licensee(s) that
is relevant to, related to, derived from or useful for the
development, registration, commercialisation, or use of the Licensed
Product for the other Party's Field and Territory, including but not
limited to all Licensed Patent Rights, and any Arising Patents or Arising
Know-how relevant to, related to, derived from or useful for the clinical
development,
registration, commercialisation, storage, use or sale of Licensed Product. Each
Party shall also promptly notify the other Party as soon as they come into
possession of clinical data related to or useful for the development and
commercialisation of Licensed Product
and Arising Know-how or Arising Patents generated by a sublicensee, by
furnishing full details thereof to the other Party. CIMYM will not share or
exchange data generated by the Parties under this Agreement with any of their
third party licensees, unless such third party licensee also agree to the
exchange (with IGK. either generally or specifically) of data generated by them
on terms no more favourable than those agreed to be IGK.

    

    4  Know-how
and Confidential Information

    

    4.1
 Provision of
Know-how. Upon IGK's reasonable written request, CIMYM shall supply IGK
with all Licensed Know-how in its possession that is relevant to, derived from
or useful for the development, registration, commercialisation, use or sale of
Licensed Product within the IGK Field and Territory. The Licensed Know-how shall
be subject to the confidentiality provisions of Clause 4.4.

    

    4.2
 Status of
Know-how. IGK acknowledges that the Licensed Know-how is subject to
further development. Accordingly, specific results cannot be guaranteed and
any results, materials, information or other items, including the Licensed
Know-how and inventions claimed in the Licensed Patent Rights (together
“Delivered Items”) to be provided under this Agreement are provided “as is” and
without any express or implied warranties, representations or undertakings. As
examples, but without limiting the foregoing, CIMYM does not give any warranty
that Delivered Items are of merchantable or satisfactory quality, are fit for
any particular purpose, comply with any sample or description, or are viable,
uncontaminated, safe or non-toxic.

    

    4.3
 Use of Know-how.
IGK agrees, not to use the Know-how for any purpose except as
expressly licensed hereby and strictly in accordance with the provisions of
this Agreement.

    

    4.4
 Confidentiality
Obligations. Each Party (“Receiving Party”) undertakes:

    

    (a) to
maintain as secret and confidential all Know-how and other Confidential
Information obtained directly or indirectly from the other Party (“Disclosing
Party”) in the course of or in anticipation of this Agreement and to respect the
Disclosing Party's rights therein,

    

    (b) to
use the same exclusively for the purposes of this Agreement,
and

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    (c)
subject to the provisions of Clause 4.7, to disclose the same only to those of
its employees, contractors and sub-licensees pursuant to this Agreement (if any)
to whom and to the extent that such disclosure is reasonably necessary for the
purposes of this Agreement.

    

    4.5
 Exceptions to
Obligations. The provisions of Clause 4.4 shall not apply to Know-how and
Confidential Information which the Receiving Party can demonstrate:

    

    (a) was,
prior to its receipt by the Receiving Party from the Disclosing Party, in the
possession of the Receiving Party and at its free disposal; or

    

    (b) is
subsequently disclosed to the Receiving Party without any obligations of
confidentiality by a Third Party who was not under a duty of confidentiality and
did not derive it directly or indirectly from the Disclosing Party;
or

    

    (c) is
or becomes generally available to the public through no act or default of the
Receiving
Party or its agents, employees, Affiliates or sub-licensees.

    

    4.6  Disclosure to Court, etc. If
the Receiving Party is required to disclose Know-how or other Confidential
Information to the courts of any competent jurisdiction, or to any
government regulatory agency or financial authority, such disclosure shall
not be a breach of Clause 4.4, provided that the Receiving Party shall (i)
inform the Disclosing Party as soon as is reasonably practicable and shall
only disclose Confidential Information to the extent so required, and (ii)
allow the Disclosing Party to seek to persuade the court, agency
or authority to have the information treated in a confidential manner,
where this is possible under the court, agency or authority's
procedures.

    

    4.7
 Disclosure to Employees.
The Receiving Party shall ensure that all of its
employees, contractors, consultants, advisers and sub-licensees pursuant to
this Agreement (if any) who have access to any of the Disclosing Party's
Know-how or other Confidential Information to which Clause 4.4 applies,
shall be made aware of and subject to these obligations and shall have
entered into written undertakings of confidentiality at least as restrictive as
Clauses 4.4 and 4.5 and prior to receiving Disclosing Party's Know-how or
Confidential Information.

    

    4.8  Ownership of Confidential
Information

    

    All
Confidential Information disclosed by the Disclosing Party shall, as between the
Parties, remain the sole and exclusive property of the Disclosing Party
including without  limitation:

    

    (a) all
ideas, concepts, information, trade secrets, know-how, business strategies
and methods relating to the Confidential Information;

    

    (b) all
physical material containing, bearing, or embodying any Confidential
Information in human or machine readable form, including, without
limitation, all documents, agreements, diagrams, charts, graphs, computer
programs, computer diskettes, and computer files; and

    

    (c) all
proprietary and intellectual property rights in the Confidential
Information, regardless of whether these items were created, generated,
developed, produced or prepared by
or on behalf of the Disclosing Party, and regardless of whether these items
came into being before or after the date hereof.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    4.9  Return of Confidential Information

    

    Upon the
request of a Disclosing Party, the Receiving Party will promptly return to
Disclosing Party, or at Disclosing Party's election, destroy all Confidential
Information of the Disclosing Party in its possession or in the possession
of its representatives. Receiving Party shall use reasonable efforts to
cause its representatives and any other Party acting under its direction or
control to return all materials containing Confidential Information, including
all copies, notes, summaries and outlines; Provided always IGK may retain a
copy of all Confidential Information disclosed to IGK pursuant to this
Agreement for the duration of this Agreement and for archival
purposes.

    

    5  Manufacturing
and Supply

    

    5.1  Clinical
Supply.  CIMAB shall supply to CIMYM and CIMYM shall supply to
IGK and its Affiliates, and IGK shall, subject to Clause 5.5 below, purchase
from CIMYM for its own use and that of its Affiliates, in finished form with one
hundred percent (100%) of IGK’s unit requirements of Licensed Product for all
clinical development purposes. Such clinical requirements shall be supplied to
IGK in accordance with the following terms and conditions:

    

    (a) In
respect of IGK's requirements for clinical trials for the purposes of seeking
Regulatory Approvals in accordance with the Development and Commercialization
Plan as outlined in Schedule 3 and agreed upon by the Parties, CIMYM shall sell
Licensed Product in finished form to IGK at a supply price of US$1,000 (one
thousand US dollars) per gram of active substance in the finished form, delivery
of which will be within 90 days of written order. Payment will be made 50% in
advance for each instalment of Licensed Product that is ordered under this
paragraph (a) when it is available for delivery. The second half of payment will
be paid within 30 days after receiving the Licensed Product.

    

    (b) For
all other supply for clinical purposes, including without limitation supply for
Phase IV studies and for studies that are not required for obtaining Regulatory
Approvals in accordance with the Development and Commercialization Plan as
outlined in Schedule 3, CIMYM shall sell Licensed Product in finished form to
IGK at a supply price equal to US$1,100 (one thousand one hundred US dollars)
per gram. Payment will be made 50% in advance for each instalment of Licensed
Product that is ordered under this paragraph (b) when it is available for
delivery. The second half of payment will be paid within 30 days after receiving
the Licensed Product.

    

    5.2  Commercial Supply. CIMAB
shall supply to CIMYM and CIMYM shall supply to IGK, and IGK shall, subject to
Clause 5.5 below, purchase from CIMYM in finished form one hundred percent
(100%) of IGK's unit requirements of Licensed Products for all commercial
sales or any other non-clinical purposes. CIMAB may elect to have such
requirements supplied to CIMYM by one or more of CIMAB’s Contract
Manufacturer(s). IGK's quantity requirements shall include those of its
Affiliates and sublicensees. The supply price that CIMYM shall charge to
IGK shall be in accordance with the following:

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    (a) For
supplies of Licensed Product to IGK until the fifth anniversary of the first
commercial sale of the Licensed Product in a Major Country the greater of (i)
25% of the Net Sales Value of the Licensed Product in the Territory and (ii)
US$1,500 (one thousand five hundred U.S. dollars) per gram of the Licensed
Product. Payment will be made $750 per gram in advance for each instalment of
Licensed Product that is ordered under this paragraph (a) when it is available
for delivery. A second payment of $750 per gram will be paid within 30 days
after receiving the Licensed Product and a final payment, applicable in the case
where the selling price exceeds US$6,000 per gram, shall be paid within 30 days
after final sale of the Licensed Product by IGK.

    

    (b) After
the fifth anniversary, the greater of (i) 20% of the Net Sales Value of the
Licensed Product in the Territory and (ii) US$1,200 (one thousand five hundred
U.S. dollars) per gram of the Licensed Product. Payment will be made $600 per
gram in advance for each instalment of Licensed Product that is ordered under
this paragraph (a) when it is available for delivery. A second payment
of $600 per gram will be paid within 30 days after receiving the Licensed
Product and a final payment, if applicable in the case where selling price
exceeds US$6,000 per gram, shall be paid within 30 days after final sale of the
Licensed Product by IGK.

    

    5.3  Specifications.  CIMAB
undertakes that all Licensed Product supplied to CIMYM (and thereafter to IGK)
will be manufactured in accordance with mutually agreed upon specifications
(inclusive of specifications in an approved Marketing Authorization) and Good
Manufacturing Practices of the European Medicines Agency and the relevant
Regulatory Authorities, and the relevant regulatory authorities in the countries
of manufacture of the Licensed Product, and will not be adulterated or
misbranded under applicable laws, regulations or guidelines, and that the
manufacturer will have in force all necessary Regulatory Approvals for the
manufacture of Licensed Product in accordance with such specifications for the
purposes of supply and use of Licensed Product in all countries of the
Territory, and will be in good standing with all Regulatory
Authorities.

    

    5.4  Supply Agreement. Licensed
Product supplied by CIMAB or CIMAB's Contract Manufacturer(s) to CIMYM and by
CIMYM to IGK for clinical and commercial purposes shall be supplied to IGK
pursuant to the terms of separate Supply Agreements. IGK, CIMYM and CIMAB shall
use good faith efforts to negotiate and enter into such supply agreements for
commercial purposes, at least six (6) months prior to the submission of a
Regulatory Application for the Licensed Product in the Territory. The Supply
Agreements shall contain forecast procedures, permitted variances from
forecasted amounts, order and delivery times, quality control and quality
assurance procedures, audits, yield ratios, maintenance of inventory, procedures
and remedies for rejection of non-conforming product, record retention,
compliance with laws, and other customary provisions. The terms of the Supply
Agreements shall be consistent with the provisions of this Clause 5, unless
otherwise agreed in writing by Parties.

    

    5.5  Supply Shortage

    

    5.5.1  CIMYM
shall notify IGK immediately upon becoming aware that CIMAB or CIMAB's Contract
Manufacturer is unable to supply CIMYM the quantity of the Licensed Product
ordered by IGK. In such circumstances, CIMYM and CIMAB shall use all
commercially reasonable endeavours to remedy such shortage.

    

    5.5.2 
In the event CIMAB is unable to supply CIMYM (and therefore IGK's) requirements
of Licensed Product for any reason, CIMAB shall allocate an amount of the
Licensed Product in its inventory so that IGK receives at least its
proportionate share of such available supplies, as determined from reasonable
forecasts and orders therefor as more specifically set forth in the Supply
Agreement.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    5.6  Right to
Manufacture

    

    5.6.1
 In the event that, other than by reason of a Force Majeure Event (as
defined in Clause 12.1), that (a) CIMAB or CIMAB's Contract Manufacturer is
unwilling or unable to manufacture Licensed Product to the specifications
required by the relevant Regulatory Authority or by the terms of any relevant
Registration Approval, or b) CIMAB or CIMAB's Contract Manufacturers is or are
unwilling or unable to supply CIMYM and therefore CIMYM is unable to supply IGK
with Licensed Product for a period of more than one calendar quarter in any
given two-year period and in such quantities in accordance with reasonable
forecasts as agreed by the Parties, IGK shall have the right to have
manufactured by a Third Party Manufacturer (as defined below) one hundred
percent (100%) of its own clinical and commercial requirements of Licensed
Product and/or the Licensed Product, in accordance with the provisions of Clause
5.6.2.

    

    5.6.2 
To enable IGK to have the Licensed Product manufactured for it in accordance
with Clause 5.6.1, the Parties shall, if the events described in Clause 5.6.1
occur, make arrangements for the transfer of Licensed Know-how relevant to or
useful for the manufacture of the Licensed Product to a manufacturer nominated
by IGK ("Third Party Manufacturer"). CIMAB shall fully cooperate with CIMYM and
IGK and take all commercially reasonable actions as shall be required to qualify
and enable such Third Party Manufacturer including, without limitation,
providing the Third Party Manufacturer without charge, such documentation,
Know-How and technical assistance, with CIMAB and IGK sharing costs on a 50:50
basis.

    

    6  Grant
of Rights

    

    6.1  Licensed Intellectual
Property

    

    6.1.1  CIMYM
hereby grants to IGK, subject to the provisions of this Agreement:

    

    (a) an
exclusive sub-license in the IGK Field and Territory (except that in South
Africa it shall be a Co-Exclusive License) under the Licensed Patent Rights with
the right to sub-license, to develop, use and sell Licensed Product but only in
the IGK Field and Territory;

    

    (b) an
exclusive sub-license in the IGK Field and Territory (except that in South
Africa it shall be a Co-Exclusive License) to use the Licensed Know-how, with
the right to sub-license, to develop, use and sell Licensed Product but only in
the IGK Field and Territory; and

    

    (c) in
the case where the circumstances described in Clause 5.6 occur, CIMAB grants IGK
a non-exclusive sub-license in the IGK Field and Territory (except that in South
Africa it shall be a Co-Exclusive License) to manufacture or to have
manufactured for IGK and its Affiliates and sublicensees, the Licensed
Product.

    

    6.1.2
 In the event that CIMAB wishes to exercise its co-exclusive rights in
South Africa, it shall notify IGK of its intended activities in such country so
as to ensure that IGK's rights are not adversely affected.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    6.2  Arising Intellectual
Property

    

    6.2.1  Arising
Intellectual Property shall be owned by the Party (which for the purposes of
this Clause may include CIM and CIMAB) that invents or creates it, and if it is
jointly invented or created by IGK, one or more of the Parties it shall be owned
jointly by those Parties (IGK, Kalbe, CIM and CIMYM) in equal, undivided shares,
subject to the provisions of this Agreement including the following
provisions:

    

    (a) It is
anticipated that Arising Know-how will be generated by clinicians and other
Persons in the course of, or arising from, clinical studies that have been
designed by the Joint Development Team. Accordingly, it is agreed that all
Arising Know-how developed in, or arising from, the work performed under the
Development and Commercialisation Plan shall be jointly owned by Parties in
equal, undivided shares, subject to the provisions of this
Agreement.

    

    6.2.2 
CIMAB and CIMYM hereby grants and agrees to grant to IGK an exclusive, fully
paid-up and royalty-free, license under Arising Intellectual Property in the IGK
Field and Territory, for the duration of this Agreement (and any extension
thereto) with the right to sub-license, to research, develop, make, have made,
import, use, sell and otherwise deal in any and all products and processes in
the IGK Field and Territory save and except that the grant made hereunder in
South Africa shall be a co-exclusive License, but only so long as the current
co-exclusive license (or any extension thereof) between the Government of South
Africa and CIMAB is in force.

    

    6.2.3 
IGK and its Affiliates hereby grant to CIMYM, CIMAB, and CIM an exclusive, fully
paid- up and royalty-free, perpetual license under IGK's Arising Intellectual
Property with a right to sub- license, research, develop, make, have made,
import, use, sell and otherwise deal in any and all products and processes in
the CIMYM Field and Territory.

    

    6.3  Formal Licenses.  If requested by
any of the Parties and at the requesting Party's administrative cost, the
Parties shall execute such formal licenses as may be necessary or appropriate
for registration with Patent Offices and other relevant authorities in the
Territory. In the event of any conflict in meaning between any such license and
the provisions of this Agreement, the provisions of this Agreement shall
prevail. The Parties shall use reasonable endeavours to ensure that, to the
extent permitted by relevant authorities, this Agreement shall not form part of
any public record.

    

    6.4  Reservation of Rights within Field
and Territory.  For the avoidance of doubt, CIMYM reserves the right
for itself and its licensees and assigns to use Licensed Product and the
Licensed Intellectual Property in the IGK Field and Territory with the prior
consent of IGK (a) for the purposes of research; and/or (b) for the purposes of
development (including clinical trials) of products with a view to obtaining
regulatory approval for such products in the CIMYM Field and Territory. If CIMYM
wishes to conduct research or development activities in the IGK Field and
Territory in accordance with the provisions of this Clause, it will so inform
IGK and give IGK a first opportunity to propose terms for an agreement with
CIMYM under which IGK would assist CIMYM with such activities at the cost
of CIMYM.

    

    6.5  No Other License. It is
acknowledged and agreed that no license is granted by CIMYM to IGK other than
the sub-license(s) expressly granted by the provisions of this Clause 6. Without
prejudice to the generality of the foregoing, CIMYM reserves all rights under
the Licensed Intellectual Property in the CIMYM Field and
Territory.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    6.6  Quality. IGK shall ensure
that all Licensed Product marketed by it is of satisfactory quality and complies
with all applicable laws and regulations in each part of the
Territory.

    

    6.7  Acknowledgment by CIMAB.
CIMAB acknowledges and agrees that CIMYM has been granted the necessary rights
and licenses to enable it to grant the licenses and sub-licenses referred to in
Clause 6 of this Agreement.

    

    7  Payments

    

    7.1  IGK
shall pay to CIMYM a non-refundable, non-creditable upfront payment of
$1,000,000, within 30 days of receipt of invoice therefor after the Commencement
Date.

    

    7.2  IGK
will pay to CIMYM the following non-refundable, non-creditable milestone
payments, within 30 days from the date of occurrence of each of the following
Events:

    

    
      
        
          
            	
                    EVENT

                  	 	
                    PAYMENT

                  	 
	 
      	 	 	 
	
                    First
      Regulatory Approval within any Major Country as a treatment for
      Glioma

                  	 	$	500,000	 
	 
      	 	 	 	 
	
                    First
      Regulatory Approval within any Major Country as a treatment for any
      indication other than Glioma (hereinafter "Indication 2'')

                  	 	$	1,100,000	 
	 
      	 	 	 	 
	
                    First
      Regulatory Approval within any Major Country as a treatment for any
      indication other than Indication 2 or Glioma (hereinafter "Indication
      3")

                  	 	$	1,100,000	 
	 
      	 	 	 	 
	
                    First
      Regulatory Approval within any Major Country as a treatment for any
      indication other than Indication 2 or 3 or Glioma (hereinafter "Indication
      4'')

                  	 	$	1,100,000	 

          

        

      

    

    

    If CIMYM
chooses to develop Licensed Product for additional indications that have not
been included

    above,
upfront and milestone payment terms will be negotiated with IGK at an
appropriate time and if agreement is reached between the Parties, will be
incorporated into an amendment to this Agreement.

    

    7.3  Royalties. IGK shall pay to
CIMYM a royalty of 15% (fifteen per cent) of Net Sales Value of Licensed
Product.

    

    7.4  Payment Dates. Royalties due
under this Agreement shall be paid within 90 days of the end of each Calendar
Quarter, in respect of sales of Licensed Product made during such Calendar
Quarter, and final royalties shall be paid within 30 days of the final sale of
the Licensed Product but in any event no later than 7 months following
termination of this Agreement for any reason.

    

    7.5  Payment Terms. All sums due
under this Agreement:

    

    (a) shall
be paid in US dollars (or such other currency as the Parties may agree in
writing) and, in the case of sales received by IGK in a currency other than US
dollars, the income shall be calculated in the other currency and then converted
into equivalent US dollars at the purchasing rate for US dollars as quoted by
HSBC bank in Singapore, as applicable, as at the close of business on the last
business day of the quarterly period with respect to which the payment is
made;

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    (b) all
sums payable by IGK hereunder shall be paid in full, without set-off or
counterclaim, including but not limited to any deduction or withholding taxes or
other liability imposed by any governmental authority or applicable law in the
Territory. In the case where IGK is required by applicable law in the Territory
to make any such deductions or withholding, IGK shall pay to CIMYM such
additional amount as will result in the receipt by CIMYM of the full amount
payable hereunder had such deduction or withholding not occurred or been
required;

    

    (c) shall
be made by the due date, failing which CIMYM may charge interest on any
outstanding amount on a daily basis at a prevailing US Prime Rate plus eight
percent (8%) then in force published by the Wall Street Journal compounded
monthly. By way of example, if the Wall Street Journal US Prime Rate is 5% and
the outstanding amount is $1000, YM may charge $.42 per day interest on such
outstanding amount.

    

    7.6  Exchange Controls, etc. If at
any time during the continuation of this Agreement IGK is prohibited from making
any of the payments required hereunder by a governmental authority in any
country then IGK will within the prescribed period for making the said payments
in the appropriate manner use its best endeavours to secure from the proper
authority in the relevant country permission to make the said payments and will
make them within 7 days of receiving such permission. If such permission is not
received within 30 days of IGK making a request for such permission then, at the
option of CIMYM, IGK shall deposit the royalty payments due in the currency of
the relevant country either in a bank account designated by CIMYM within such
country or such royalty payments shall be made to an associated company of CIMYM
designated by CIMYM and having offices in the relevant country.

    

    7.7  Royalty Statements. IGK shall
send to CIMYM at the same time as each royalty payment is made in accordance
with Clause 7.3 a statement setting out, in respect of each country in the
Territory in which Licensed Product is sold, the types of Licensed Product sold,
the quantity of each type sold, and the total Net Sales Value in respect of each
type, expressed both in local currency and US Dollars and showing the conversion
rates used during the period to which the royalty payment relates.

    

    7.8  Records

    

    7.8.1  IGK
and its Affiliates shall keep at its normal place of business detailed and up to
date records and accounts showing the quantity, description, Gross Sales Value
and Net Sales Value of Licensed Product, all source documents and other records
corresponding to Gross Sales Value, Net Sales value or any deductions from Gross
Sales Value and from Net Sales Value and the amount of Milestone Receipts
received by it in respect of Licensed Product, on a country-by-country basis,
and being sufficient to ascertain the payments due under this
Agreement.

    

    7.8.2  IGK
and its Affiliates shall make such records and accounts available, on reasonable
notice, for inspection during business hours by an independent chartered
accountant nominated by CIMYM for the purpose of verifying the accuracy of any
statement or report given by IGK to CIMYM under this Agreement. The accountant
shall be required to keep confidential all information learned during any such
inspection, and to disclose to CIMYM only such details as may be necessary to
report on the accuracy of IGK's or its Affiliates statement or report. CIMYM
shall be responsible for the accountant's charges unless the accountant
certifies that there is an inaccuracy of more than 5% (five percent) in any
royalty statement, in which case IGK and its Affiliates shall pay his charges in
respect of that inspection. If the inspection shows that IGK or its Affiliates
owes a payment to CIMYM under this Agreement, IGK shall promptly make such
payment.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    7.8.3  IGK
shall ensure that CIMYM has the same rights as those set out in this Clause 7.8
in respect of any Affiliate of IGK that is sub-licensed under Licensed
Intellectual Property pursuant to this Agreement.

    

    8  Diligence

    

    8.1  IGK
shall use Diligent and Reasonable Efforts to develop and commercially exploit
Licensed Product to the maximum extent throughout the Territory. Without
limiting IGK's obligations under the previous sentence of this Clause 8.1, IGK
shall develop and commercially exploit Licensed Product in accordance with the
Development and Commercialisation Plan.

    

    9  Intellectual
Property

    

    9.1  Obtain and Maintain the Licensed
Patent Rights

    

    9.1.1  CIMYM
shall, at its cost and expense:

    

    (a)
diligently seek to obtain valid patents in the name of CIM pursuant to each of
the Licensed Patent Rights; and

    

    (b) pay
all prosecution, maintenance, and renewal fees in respect of the Licensed Patent
Rights as and when due;

    

    provided
that if CIMYM elects to abandon any such application or not to maintain any
Licensed Patent (or to cease funding such application or patent) within IGK's
Field and Territory (collectively "Expiring Patents") it shall give 3 months'
prior written notice to IGK to permit IGK to maintain the Expiring Patents in
the name of CIM and IGK, failing which, IGK shall not have any continuing rights
under such Expiring Patents.

    

    9.2  Obtain and Maintain the Arising
Patents

    

    9.2.1  IGK
shall consult with CIMYM, CIM and CIMAB in relation to the filing and
maintenance of any Arising Patents ("Arising Patents"). CIMYM shall, or shall
ensure that its Affiliates or sub-licensees shall, at its own cost and
expense:

    

    (a)
Diligently seek to obtain valid patents in the names of the inventing parties,
as specified in Clause 6.2.1, in countries agreed upon by CIMAB and CIMYM for
any Arising Inventions; and

    

    (b) pay
all prosecution, maintenance, and renewal fees in respect of the Arising Patents
as and when due,

    

    provided
that if CIMYM,  its Affiliates or sub-licensees wish to abandon or not
maintain any such application or not to maintain any such Arising Patent (or to
cease funding such application or patent) (collectively "Abandoned Patents")
within the IGK Field and Territory, it shall give 3 months' prior written notice
to IGK and on the expiry of such notice period with respect to such Abandoned
Patents in the IGK Field and Territory, CIMYM shall assign all rights and
interest in such Abandoned Patents or patent application in question to be
assigned to IGK and CIMYM shall have no continuing rights under such Arising
Patents in the IGK Field and Territory.

    

    9.2.2  Each
Party shall inform the other Party promptly if it becomes aware of any alleged
infringement or potential infringement of any of the Licensed Patent Rights in
the IGK Field and Territory. The Parties shall consult each other on the best
way to respond to such infringement.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    IGK shall
be responsible, at its discretion, for taking action against infringers of the
Arising Patents in the IGK Field and Territory at its sale expense, and it shall
be entitled to retain any damages or other payments or benefits obtained by such
action in the IGK Field and Territory, after reimbursing CIMYM and CIMAB for any
reasonable out-of-pocket expenses incurred in assisting it in such action. If
IGK declines to take action, then CIMYM shall be entitled to take action against
the Third Party infringer at CIMYM's sole expense and CIMYM shall be entitled to
all damages or other sums received from such action, after reimbursing IGK for
any reasonable out-of-pocket expenses incurred in assisting it in such action.
If the alleged infringement is both within and outside the IGK Field and
Territory, the Parties shall also co-operate with CIMYM's and CIMAB's other
licensees (if any) in relation to any such action and shall divide the costs of
such action proportionately among IGK and CIMYM's and CIMAB's other licensees
who participate in such action. The apportionment of costs between licensees
shall be decided by CIMYM, acting reasonably.

    

    9.3  Infringement of Third Party
Rights

    

    9.3.1  If
any warning letter or other notice of infringement is received by a Party, or
legal suit or other action is brought against a Party, alleging infringement of
Third Party rights in the manufacture, use or sale of the Licensed Product or
use of any Licensed Patent Rights within the IGK Field and Territory, that Party
shall promptly provide full details to the other Party, and the Parties shall
discuss the best way to respond.

    

    9.3.2  CIMYM
shall have the right but not the obligation to defend such suit and shall have
the right to settle with such Third Party, provided that if any action or
proposed settlement involves the making of any statement, express or implied,
concerning the validity of any Licensed Patent Rights within the IGK Field and
Territory, the consent of IGK must be obtained before taking such action or
making such settlement, such consent not to be unreasonably withheld or
delayed.

    

    9.4  Third Party Intellectual
Property. For the avoidance of doubt IGK shall be solely responsible for
obtaining and paying for any additional licenses and other rights that may be
required to enable IGK or its Affiliates to commercialise Licensed Product in
the Territory. If the sale of the Licensed Product is found to infringe the
intellectual property rights of a Third Party, and results in the payment of
royalties or other compensation by IGK (or its Affiliates) to a Third Party
including legal fees, IGK may reduce us royalty payments to CIMYM under Clause
7.3 by 50% (fifty percent) of the royalties or other compensation paid to the
Third Party in respect of sales of Licensed Product in the Territory, subject to
the following conditions:

    

    (a) The
royalty due from IGK to CIMYM on the sale of the Licensed Product shall not be
reduced below 12%; and

    

    (b) Such
reductions shall only be made where the Third Party liability arises from the
use of the inventions claimed in the Licensed Patents and shall not be made in
respect of any other inventions, improvements or other features that IGK chooses
to incorporate into the Licensed Product.

    

    9.5  Product Names. IGK may use
its own trade mark for the Licensed Product and shall be responsible for
deciding, in consultation with CIMYM, the trade mark to be applied to the
Licensed Product in the IGK Field and Territory. IGK will be responsible for
applying for any such trade mark in the Territory, at its sale cost. CIMYM
acknowledges that it has no objection to the trade mark "TheraCIM". CIMYM will
be responsible for applying for an international, non-proprietary name ("INN")
for the Licensed Product at its sale cost. IGK acknowledges that it has no
objection to the INN "NIMOTUZUMAB".

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    10  Representations,
Warranties and Liability

    

    10.1  Representations and Warranties by
CIMYM. CIMYM represents and warrants that:

    

    (a) it
has all requisite corporate power and authority to enter into and perform its
obligations pursuant to this Agreement and to grant the sub-licenses herein
granted;

    

    (b) it
has not done, and will not do nor agree to do during the continuation of this
Agreement, any of the following things if to do so would be inconsistent with
the exercise by IGK of the rights granted to it under this Agreement,
namely:

    

    (i) grant
or agree to grant any rights in the Licensed Patent Rights in the IGK Field and
Territory; or

    

    (ii)
assign, mortgage, charge or otherwise transfer any of the Licensed Patent Rights
in the IGK Field and Territory;

    

    (c) it is
not aware (but without having carried out any searches or investigations) that
any Third Party (other than CIMYM's licensor(s)) owns or claims any rights in
the Licensed Patent Rights;

    

    (d) it is
a corporation incorporated and validly existing under the laws of its
jurisdiction of incorporation; and

    

    (e) the
execution, delivery and performance of this Agreement by it have been duly and
validly authorized by all necessary corporate action on its part and this
Agreement is a legal, valid and binding obligation enforceable against it in
accordance with its terms, except as enforceability may be subject to
bankruptcy, insolvency and other laws affecting the rights of creditors
generally and except that equitable remedies may be granted only in the
discretion of a court of competent jurisdiction.

    

    10.2  Representations and Warranties by
IGK and Kalbe. Kalbe and IGK jointly and severally represent, warrant and
undertake:

    

    (a) that
IGK has, and will continue to have, sufficient financial and other resources to
fulfil its obligations under this Agreement;

    

    (b) that
IGK has obtained all necessary authorisations from its supervisory board and
investors to use such resources and fulfil such obligations;

    

    (c) IGK
has all requisite corporate power and authority to enter into and perform its
obligations pursuant to this Agreement;

    

    (d) IGK
is a corporation incorporated and validly existing under the laws of its
jurisdiction of incorporation; and

    

    (e) the
execution, delivery and performance of this Agreement by IGK have been duly and
validly authorized by all necessary corporate action on its part and this
Agreement is a legal, valid and binding obligation enforceable against it in
accordance with its terms, except as enforceability may be subject to
bankruptcy, insolvency and other laws affecting the rights of creditors
generally and except that equitable remedies may be granted only in the
discretion of a court of competent jurisdiction.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    10.3  No Other
Warranties

    

    10.3.1  Each
of IGK and CIMYM acknowledges that, in entering into this Agreement, it does not
do so in reliance on any representation, warranty or other provision except as
expressly provided in this Agreement, and any conditions, warranties or other
terms implied by statute or common law arc excluded from this Agreement to the
fullest extent permitted by law.

    

    10.3.2  Without
limiting the scope of Clause 10.3.1, CIMYM does not give any warranty,
representation or undertaking:

    

    (a) as to
the efficacy or usefulness of any of the Licensed Intellectual Property;
or

    

    (b) that
any of the Licensed Patent Rights is or will be valid or subsisting or (in the
case of an application) will proceed to grant; or

    

    (c) that
the use of any of the Licensed Intellectual Property, the manufacture, sale or
use of the Licensed Product or the exercise of any of the rights granted under
this Agreement will not infringe any other intellectual property or other rights
of any other person; or

    

    (d) that
the Licensed Know-how or any other information or materials communicated or
provided by CIMYM to IGK under or in connection with this Agreement will produce
Licensed Product of satisfactory quality or fit for the purpose for which IGK
intended; or

    

    (e) as
imposing any liability on CIMYM in the event that any Third Party supplies
Licensed Product to customers located in the Territory.

    

    10.4
Indemnity and
Insurance. IGK shall indemnify and hold harmless CIMYM, CIM and (except
as otherwise provided in any Supply Agreement) CIMAB and their respective
Affiliates and their respective officers, directors, employees, consultants,
agents and representatives (the "Indemnitees") against all Third Party Claims
which may be asserted against or suffered by any of the Indemnitees and which
relate to:

    

    (a) the
use of any Delivered Items; or

    

    (b) the
manufacture, distribution, sale, supply or use of the Licensed Product or any
other products or services which incorporate any Delivered Items,

    

    by or on
behalf of IGK or its Affiliates, or subsequently by any Third Party under
license from IGK, including without limitation Claims based on product liability
laws. For the duration of this Agreement, IGK shall maintain clinical trials and
product liability insurance with a reputable insurer in an amount not less than
the minimum amount required by law or best industry practice in each country of
the Territory (or, in any country, if no such law or practice exists in that
country, in an amount of at least $10,000,000) per Claim or series of
Claims).

    

    10.4.1  At
the option of IGK, CIMYM will either (a) use commercially reasonable efforts to
seek extension of its (or its Affiliate, YM BioSciences, Inc.'s) current
clinical trial and product liability insurance to cover claims against IGK in
the amount of at least $10,000,000 aggregate limit or such higher amount as may
be required by law within the Territory, as IGK may be required to obtain
pursuant to Clause 10.4 ("Insurance Coverage"), at the best commercially
available policy premium; and in such a case, IGK will bear the premium for such
extension; or (b) use commercially reasonable efforts to assist IGK to obtain
Insurance Coverage on the best commercially reasonable terms.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    10.5  Limitation of Liability.
Subject to Clause 10.4, but notwithstanding any other provision of this
Agreement, no Party shall be liable to any other Party to this Agreement in
contract, tort, negligence, breach of statutory duty or otherwise for Claims of
any nature whatsoever incurred or suffered by that other party or its Affiliates
of an indirect or consequential nature including without limitation any economic
loss or other loss of turnover, profits, business or goodwill.

    

    11  Duration
and Termination

    

    11.1  Commencement and Termination by
Expiry. This Agreement, and the rights granted hereunder, shall come into
effect on the Commencement Date and, unless terminated earlier in accordance
with this Clause 11, shall continue in force in each country in the Territory
until the latest of the fifteenth anniversary of the date of the first
commercial sale of Licensed Product in such country in the Territory by IGK or
its Affiliates or the date when all Licensed Patent Rights have expired or been
abandoned in accordance with the provisions of this Agreement, whichever is
later; and on such date this Agreement and the rights granted hereunder shall
terminate automatically by expiry.

    

    11.2  Early
Termination

    

    11.2.1  IGK
may terminate this Agreement at any time on 120 days’ notice in
writing  to CIMYM.

    

    11.2.2  Without
prejudice to any other right or remedy, either of CIMYM or IGK may terminate
this Agreement at any time by notice in writing to the other of them ("Other
Party"), such notice to take effect as specified in the notice:

    

    (a) if
the Other Party (which in the case of IGK shall include any Affiliate of IGK) is
in material breach of this Agreement and. in the case of a breach capable of
remedy within 60 days, the breach is not remedied within 60 days of the Other
Party receiving notice specifying the breach and requiring its remedy;
or

    

    (b) if
the Other Party (which in the case of IGK shall include any Affiliate of IGK)
becomes insolvent, or if an order is made or a resolution is passed for the
winding up of the Other Party (other than voluntarily for the purpose of solvent
amalgamation or reconstruction), or if an administrator, administrative receiver
or receiver is appointed in respect of the whole or any part of the Other
Party's assets or business, or if the Other Party makes any composition or
proposal with its creditors or takes or suffers any similar or analogous action
in consequence of debt; or

    

    (c) if
the first Phase II clinical trial for the Licensed Product within the Field in
the Territory has not commenced within a period of one and a half years after
the Commencement Date; or

    

    (d) if
the first Regulatory Approval for marketing the Licensed Product within the
Field in the Territory is not obtained within a period of four (4) years after
the Commencement Date while all the required documentation has been supplied by
CIMYIM and CIMAB to IGK in a timely manner.

    

    11.2.3  CIMYM
may forthwith terminate this Agreement by giving written notice to IGK if IGK or
any of its Affiliates commences legal proceedings, or assists any Third Party to
commence legal proceedings, to challenge the validity of any of the
Patents.

    

    11.2.4  The
Parties acknowledge and agree that IGK's remedy for any breach by CIMAB of its
obligations under Clause 5 shall be as set out in any Supply Agreement that
CIMYM and IGK may execute pursuant to Clause 5.4. Accordingly, breach of Clause
5 shall not entitle any Party to terminate this Agreement.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    11.3  Consequence of
Termination

    

    11.3.1  Upon
termination or expiration of this Agreement for any reason:

    

    (a) If
termination occurs after the first commercial sale of Licensed Product, IGK
shall be entitled to sell, use or otherwise dispose of (subject to payment of
royalties under Clause 7.3) any unsold or unused stocks of the Licensed Product
for a period of 6 months following the date of termination following which it
must destroy al1 such Licensed Product; and if termination occurs prior to the
first commercial sale of Licensed Product, IGK shall forthwith return all such
stocks of Licensed Product and Licensed Know-how to CIMYM at IGK's sale
expense;

    

    (b)
subject to paragraph (a) above, IGK shall no longer be sub-licensed to use or
otherwise exploit in any way, either directly or indirectly, any of the Licensed
Intellectual Property or Arising Intellectual Property;

    

    (c)
subject to paragraph (a) above, IGK shall consent to the cancellation of any
formal sub-license granted to it, or of any registration of it in any register,
in relation to any of the Licensed Patent Rights;

    

    (d) the
provisions of Clause 4, except Clause 4.1 and 4.2 shall survive termination and
continue in force for a period of five years after the effective date of
termination, where applicable. For clarification, IGK and its Affiliates shall
have no further right to use Licensed Know-how following termination or
expiration of this Agreement;

    

    (e) the
provisions of Clauses 4, 6.2.3, 7, 10, and 12 are intended to survive the
termination or expiry of this Agreement and shall survive the termination or
expiration of this Agreement; and

    

    (f) any
and all rights and obligations accrued under this Agreement prior to termination
or expiration shall survive. Notwithstanding the foregoing, neither Party shall
be under any further obligation to the other and CIM and CIMYM shall have the
right to issue licenses under the License Patent Rights to any Third Party
within IGK's Field and Territory.

    

    (g) IGK
shall cease and shall cause any Third Party Manufacturer to cease manufacture of
Licensed Product and destroy any materials used in the production or manufacture
of Licensed Product within thirty (30) days.

    

    11.3.2  Upon
termination of this Agreement for any reason otherwise than (i) in accordance
with Clause 11.1 or (ii) because or due to the breach of this Agreement by
CIMYM, at CIMYM's request, IGK shall:

    

    (a)
transfer to CIMYM all clinical and other data relating to the development of
Licensed  Product;

    

    (b) to
the extent possible, seek to have any Regulatory Approvals (including without
limitation product licenses and pricing approvals) and other permits and
applications transferred into the name of CIMYM or its nominee;

    

    (c) grant
CIMYM an exclusive, perpetual, fully paid up, royalty free, worldwide license,
with the rights to grant sub-licenses without the consent of IGK, under all
Arising Intellectual Property jointly owned by the Parties; and

    

    (d) grant
CIMYM or its nominee the right to continue to use any product name that had been
applied to the Licensed Product prior to termination of this
Agreement.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    12  General

    

    12.1  Force Majeure. None of the
Parties shall be liable for any loss, injury, delay, damage or other casualty
suffered or incurred by any other Party due to strikes, lockouts, labour
disputes, riots, storms, fires, explosions, acts of God, war or any other causes
that are beyond the reasonable control of that Party (each, a "Force Majeure
Event"), and failure or delay by a Party in performance of any of its
obligations under the Agreement due to one or more Force Majeure Events shall
not be considered a breach of this Agreement.

    

    The Party
whose performance is affected by a Force Majeure Event shall make reasonable
efforts to remedy the situation and remove, so far as possible, and with
reasonable dispatch, the cause of its inability to perform or comply, provided
however, that settlement of labour disputes, strikes, and lockouts shall be
wholly within the discretion of the Party involved.

    

    If a
Force Majeure Event exists for more than ten (10) consecutive days, the Parties
shall meet to negotiate a mutually satisfactory solution to the problem. Nothing
herein shall relieve the Parties of their obligations to make payments when due
hereunder.

    

    12.2  Language and Amendment. This
Agreement is made in the English language and may only be amended in the English
language in writing signed by duly authorised representatives of the Parties. In
the event of any conflict in meaning between the English language version and
any translation of this Agreement, the English language version shall
prevail.

    

    12.3  Assignment and Third Party
Rights

    

    12.3.1  Subject
to Clause 12.3.2 below, no Party shall assign, mortgage, charge or otherwise
transfer any rights or obligations under this Agreement, nor any of the Patents
or rights under the Patents, without the prior written consent of the other
Parties.

    

    12.3.2  With
the prior written consent of the other Parties, a Party may assign all its
rights and obligations under this Agreement together with its rights in the
Patents to any company to which it transfers all or substantially all of its
assets or business in the Field, provided that the assignee undertakes to the
other Party to be bound by and perform the obligations of the assignor under
this Agreement.

    

    12.4  Waiver. No failure or delay
on the part of either Party to exercise any right or remedy under this Agreement
shall be construed or operate as a waiver thereof, nor shall any single or
partial exercise of any right or remedy preclude the further exercise of such
right or remedy.

    

    12.5  Invalid Clauses. lf any of
the within terms, conditions or provisions or the application thereof to any
Person or circumstance shall at any time or to any extent, be invalid or
unenforceable at law such term, condition, or provisions shall be severed from
the remainder hereof which shall be affected thereby, and each and every time
and in each and every circumstance in which reference is made hereto each term,
covenant, condition and provision hereof shall be valid and be enforced to the
fullest extent permitted by law.

    

    12.6  No Agency. Neither Party
shall act or describe itself as the agent of the other, nor shall it make or
represent that it has authority to make any commitments on the other's
behalf.

    

    12.7  Interpretation. In this
Agreement:

    

    (a) the
headings are used for convenience only and shall not affect its
interpretation;

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    (b)
references to persons shall include incorporated and unincorporated persons;
references to the singular include the plural and vice versa; and references to
the masculine include the feminine;

    

    (c)
references to Clauses and Schedules mean clauses of, and schedules to, this
Agreement;

    

    (d)
references to any Party shall include their permitted successors and permitted
assignees;

    

    (e)
references to any license shall mean, where the context requires, a
sub-license;

    

    (f) where
the word "including" is used, it shall be understood as meaning "including
without limitation"; and

    

    (g)
references to the grant of "exclusive" rights shall mean that the person
granting the rights shall neither grant the same rights (in the same Field and
Territory and in respect of the same Licensed Product) to any other person, nor
exercise those rights directly to the extent that and for as long as the
Licensed Product is within Valid Claims of unexpired Licensed Patent Rights or,
to the extent that the Licensed Product is protected by Licensed Know-how that
have not become known and available to the public.

    

    12.8  Notices

    

    12.8.1  Any
notice to be given under this Agreement shall be in writing and shall be sent by
first class mail, air mail or by courier, or by fax (confirmed by first class
mail or air mail) to the address of the relevant Party set out at the head of
this Agreement, or to the relevant fax number set out below, or such other
address or fax number as that Party may from time to time notify to the other
Party in accordance with this Clause 12.8. The fax numbers of the Parties are as
follows:

    

    
      
        	
                Party

              	
                Fax
      number

              
	
                CIMYM

              	
                001
      905 629 4959

              
	
                CIMAB

              	
                0053
      7 273 3509

              
	
                IGK

              	
                +622145850726

              

      

    

    

    12.8.2  Notices
sent as above shall be deemed to have been received three working days after the
day of posting (in the case of inland first class mail or national courier), or
seven working days after the date of posting (in the case of air mail or
international courier), or on the next working day after transmission (in the
case of fax messages, but only if a transmission report is generated by the
sender's fax machine recording a message from the recipient's fax machine,
confirming that the fax was sent to the number indicated above and confirming
that all pages were successfully transmitted).

    

    12.9  Law, Dispute Resolution. The
validity, construction and performance of this Agreement shall be governed by
English law. Any dispute arising out of or in connection with this Agreement
shall first be referred to the Joint Development Team for resolution. If the
Joint Development Team is unable or unwilling to resolve such dispute within 30
days of the dispute being referred to it, the dispute shall be referred to the
Chief Executive Officers of the Parties in dispute for resolution. If the Chief
Executive Officers of the Parties in dispute are unable or unwilling to resolve
such dispute within 28 days of the dispute being referred to them, either
Development Team Party may refer the dispute to mediation in accordance with the
Model Mediation Procedure of the Centre for Effective Dispute Resolution
("CEDR") in London. Unless otherwise agreed by the Development Team Parties, the
mediator will be nominated by CEDR. To initiate the mediation procedure, a
Development Team Party must give notice in writing (“ADR Notice”) to the other
parties to the dispute, requesting mediation. A copy of the request should also
be sent to CEDR. The mediation will start not later than 28 days after the date
of the ADR Notice. If the Parties are unable to resolve the dispute through
mediation, or none of the Parties refers the dispute to mediation, the dispute
shall be referred to and finally resolved by arbitration by a single arbitrator
in London under the Rules of the London Court of International Arbitration (the
"Rules"), which Rules are deemed to be incorporated by reference into this
Clause. The language to be used in the arbitral proceedings shall be English and
the place of arbitration shall be London, UK. The arbitrator shall be chosen by
the Parties or, failing agreement as to the choice of arbitrator within 28 days
of one Party requesting that an arbitrator by chosen, appointed in accordance
with the Rules. However, nothing in this Agreement shall prevent a Party from
seeking an interim injunction or other equitable remedy in any court of
competent jurisdiction.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    12.10  Further Action. Each Party
agrees to execute, acknowledge and deliver such further instruments, and do all
further similar acts, as may be necessary or appropriate to carry out the
purposes and intent of this Agreement.

    

    12.11  Announcements. Neither Party
shall make any press or other public announcement concerning any aspect of this
Agreement, or make any use of the name of the other Party in connection with or
in consequence of this Agreement, without the prior written consent of the other
Party, except as may be required by law or by the rules of any stock exchange on
which either Party is listed. The Parties shall agree a form of press release
for issue on signature of this Agreement.

    

    12.12  Entire Agreement. This
Agreement, including its Schedules, sets out the entire agreement between the
Parties relating to its subject matter and supersedes all prior oral or written
agreements, arrangements or understandings between them relating to such subject
matter. The Parties acknowledge that they are not relying on any representation,
agreement, term or condition that is not set out in this Agreement. Nothing in
this Agreement excludes liability for fraud.

    

    12.13  Third Party Rights. This
Agreement is not made for the benefit of, nor shall any of its provisions be
enforceable by, any person other than the parties to this Agreement and their
respective successors and permitted assignees.

    

    12.14  Non-compete. IGK and its
Affiliates warrants, represents, acknowledges and agrees, in respect of it and
its Affiliates, that:

    

    (a) they
do not have any interest in any technology that competes with the Licensed
Intellectual Property, nor is any of them engaged in any research or development
activities with respect to any product that would compete with the Licensed
Products; and

    

    (b) for
so long as this Agreement remains in force and for a period of one (1) year
thereafter, they will not enter into any agreement with any Person other than
CIMAB or CIMYM for the development or marketing of any product that is, or
contains, (i) any other anti-EGF-receptor inhibitor, (ii) any product or
component or sequence of EGF-R, EGF-R ligands, or any small molecule tyrosine
kinase inhibitor, or (iii) covered under the scope of any Licensed Patent Rights
or Licensed Know-how, unless specifically authorized by each of/all of CIMAB,
CIMYM and Affiliates if applicable.

    

    Agreed by the Parties through
their authorised signatories:

    

    For and
on behalf of CIMYM,
Inc.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    
      
        	
                signed

              	
                signed

              
	 
      	 
      
	
                David
      G.P. Allan

              	
                Sean
      E.L. Thompson

              
	 
      	 
      
	
                Director

              	
                Director,
      Corporation Development

              
	 
      	 
      
	
                date
      31-Oct -05

              	
                date
      31-Oct-05

              
	 
      	 
      
	
                For
      and on behalf of CIMAB
      S.A.

              	 
      
	 
      	 
      
	
                signed

              	
                signed

              
	 
      	 
      
	
                Norkis
      Arteaga Morales

              	
                Nornando
      Iznaga-Escobar

              
	 
      	 
      
	
                General
      Manager

              	
                Head,
      Division of Business and Development

              
	 
      	 
      
	
                date

              	
                date
      19-Dec-05

              
	 
      	 
      
	
                For
      and on behalf of

              	
                For
      and on behalf of

              
	
                Innogene
      Kalbiotech Private Limited

              	
                P.T.
      Kalbe Farma, Tbk

              
	 
      	 
      
	
                signed

              	
                signed

              
	 
      	 
      
	
                Rikrik
      IIyas

              	
                Johannes
      Setijono

              
	 
      	 
      
	
                Director

              	
                President
      Director

              
	 
      	 
      
	
                date
      11-Nov-05

              	
                date
      11-Nov-05

              

      

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    Schedule
I

    Licensed
Patent Rights

    

    The
patents and patent applications listed in this Schedule are, or may become,
relevant to this Agreement, but they also contain other rights not licensed
under this Agreement. Thus their inclusion here is limited to the extent if any
that they would protect the exploitation of Licensed Product for use within the
IGK Field and in the Territory.

    

    PCT/CU2003/000012.

    

    Patent
Numbers:

    

    
      
        
          	
                  Thailand:

                	
                  To
      Be Determined

                
	 
      	 
      
	
                  Malaysia:

                	
                  To
      Be Determined

                
	 
      	 
      
	
                  Singapore:

                	
                  200502422-9

                
	 
      	 
      
	
                  Indonesia:

                	
                  200501212

                
	 
      	 
      
	
                  Philippines:

                	
                  To
      Be Determined

                
	 
      	 
      
	
                  Taiwan:

                	
                  To
      Be Determined

                
	 
      	 
      
	
                  South
      Africa:

                	
                  To
      Be Determined

                
	 
      	 
      
	
                  Myanmar:

                	
                  To
      Be Determined

                
	 
      	 
      
	
                  Laos:

                	
                  To
      Be Determined

                
	 
      	 
      
	
                  Cambodia:

                	
                  To
      Be Determined

                
	 
      	 
      
	
                  Brunei:

                	
                  To
      Be Determined

                
	 
      	 
      
	
                  Republic
      of Congo

                	
                  To
      Be Determined

                
	 
      	 
      
	
                  Nigeria

                	
                  To
      Be Determined

                

        

      

    

     

    International
Filing Date: 22 October 2003 (22.10.2003)

    

    
      	
              Title:

            	
              METHOD
      OF OBTAINING CELL LINES IN A PROTEIN- FREE MEDIUM AND CELL LINES THUS
      OBTAINED

            

    

    

    
      	
              Applicant:

            	
              CENTRO
      DE INMUNOLOGIA MOLECULAR

            

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    Schedule
2

    Licensed
Know-how and Confidential Information

    

    1.           All
documentation that has been submitted by YM BioSciences, Inc. to the Health
Protection and Food Branch of Health Canada in connection with an application
for an Investigational New Drug Submission for the Licensed Product in
Canada.

    

    2.           All
preclinical, clinical trial and manufacturing data generated by
CIMAB.

    

    3.           Any
additional data submitted to Korean FDA.

    

    4.           Any
additional data submitted to EMEA.

    

    5.           Any
additional data submitted to the Indian regulatory authority.

    

    6.           Any
additional data submitted to the Chinese regulatory authority.

    

    7.           Any
other data submitted to any regulatory authority by current and future sub-
licensees of the Licensed Product, subject to any confidentiality obligations to
Third Parties if applicable.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    Schedule
3

    Initial
Development and Commercialisation Plan

    

    Part
A: Initial Development Program

    

    The
development program will include:

    

    1.           IGK
will run a study in Head & Neck cancer in the local population. It is
provisionally estimated that the study will be a non-randomized study combining
radiation with TheraCIM in 40 patients.

    

    2.           New
indications to be determined.Unassociated Document

    (I) CIMYM
Biosciences Inc.

    

    (2) CIMAB
S.A.

    

    and

    

    (3)
Daiichi Pharmaceutical Co., Ltd.

    

    License
Agreement

    Relating
to Nimotuzumab (TheraCIM h-R3)

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    License
Agreement

     

    This
Agreement dated the 25th day of July, 2006 is made among:

     

    (1) CIMYM Biosciences Inc.
(company registration number 12142) ("CIMYM"), a company
amalgamated
under the laws of Ontario, whose principal place of business is at 5045 Orbitar
Drive,
Building 11, Suite 400 Mississauga, Ontario L4W 4Y4; and

    

    (2) CIMAB S.A. (company
registration number 107/92) ("CIMAB"), a company
incorporated in Cuba,
whose principal place of business is at 206 Street, No. 1926, e/19 y 21, Atabey,
Playa, Havana
City, Cuba; and

    

    (3) Daiichi Pharmaceutical Co.,
Ltd. (company registration number 0199-10-034855) ("DAIICHI") a company
incorporated in Japan, whose principal place of business is at 14-10, Nihonbashi
3-Chome, Chuo-ku, Tokyo, 103-8234, Japan.

     

    Recitals:

     

    A. CIMYM
has been granted by CIMAB the exclusive license, with the right to sub-license,
of certain
Licensed Patent Rights (as defined below) and certain Licensed Know-how (as
defined below)
and other rights relating to research, development, marketing and selling the
Product (as defined
below) in several territories including Japan.

     

    B. CIMAB
is one of the shareholders of CIMYM and is entering into this Agreement
principally in order to
assume the manufacturing and supply obligations set out in Clause 8 and to
provide Product
data generated by CIMAB's licensees set out in Clause 4.4.

     

    C.
DAIICHI is a fully integrated pharmaceutical company that wishes to evaluate the
further development
and commercialisation of the Product for the treatment of cancer in humans in
the Territory
(as defined below) and in accordance with the provisions of this
Agreement.

     

    D.
DAIICHI expressed its desire to obtain a license to develop and commercialize
the Product in the Territory.

     

    E. CIMYM
is willing to grant to DAIICHI, and DAIICHI is willing to accept, a license
within the DAIICHI Field and Territory (as defined below), under certain terms
and conditions and in accordance with the provisions of this
Agreement.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    It
is agreed as follows:

     

    1   Definitions

     

    In this
Agreement, the following words shall have the following meanings:

     

    
      
        	
                Affiliate

              	 
      	
                Any
      entity or Person that controls, is controlled by, or is under common
      control with that Party. For the purposes of this definition, "control"
      shall mean direct or indirect beneficial ownership of 50% (or, outside a
      Party's home territory, such lesser percentage as is the maximum,
      permitted level of foreign investment) or more of the share capital, stock
      or other participating interest carrying the right to vote or to
      distribution of profits of that entity or person, as the case may
      be.

              
	 
      	 
      	 
      
	
                Arising
      Intellectual Property

              	 
      	
                Any
      and all of the Arising Patents and the Arising
Know-how.

              
	 
      	 
      	 
      
	
                Arising
      Know-how

              	 
      	
                Any
      and all trade secrets, know-how and technical, scientific, commercial and
      all other information generated by any Party or its Affiliates or
      sub-licensees during the term of this Agreement that relates to any of the
      Licensed Intellectual Property or the Product, in each case to the extent
      that such information is relevant, related to, derived from or useful for
      the clinical development, registration, commercialisation, storage, use or
      sale of the Product. Arising Know-how includes any scientific or
      regulatory data used for Regulatory
      Applications and Regulatory Approvals (including clinical trial data
      generated by any Party or its sub-licensees), and development and
      marketing plans and activities.

              
	 
      	 
      	 
      
	
                Arising
      Patents

              	 
      	
                Any
      and all patents and patent applications that may be applied for or
      obtained in respect of any invention(s) made by any Party or its
      Affiliates or sub-licensees during the term of this Agreement and which
      relate to any Licensed Intellectual Property or the Product, together with
      any continuations, continuations in part, extensions, reissues, divisions,
      and any patents, supplementary protection certificates, conversion and
      similar rights that are based on or derive priority from the
      foregoing.

              
	 
      	 
      	 
      
	
                CIMAB’s
      Contract Manufacturer

              	 
      	
                Any
      Person that may be contracted by CIMAB to manufacture the Licensed
      Product, or any component or ingredient thereof, in accordance with the
      provisions of this Agreement.

              
	 
      	 
      	 
      
	
                CIMYM/CIMAB
      Field

                and
      Territory

              	 
      	
                (a)    outside
      the Territory, all fields (including the Field); and

                (b)    within
      the Territory, all fields other than the Field.

              
	 
      	 
      	 
      
	
                Commencement
      Date

              	 
      	
                The
      date of execution of this Agreement by the Parties (or, if they sign on
      different dates, the last date of signature of this Agreement by a
      Party).

              
	 
      	 
      	 
      
	
                Competitive
      Product

              	 
      	
                Any
      product, which may compete with or is substantially similar to the
      Licensed Product, which is comprised of:

              
	 
      	 
      	 
      
	 
      	 
      	
                (a)
      other anti-EGF-R antibodies, single chain, fragments and peptides derived
      from antibody molecules; or

              
	 
      	 
      	 
      
	 
      	 
      	
                (b)
      any molecule that interacts through extracellular domain of EGF-R, except
      for such molecule that interacts with intracellular or transmembrane
      domain of EGF-R; or

              

      

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      
        	 
      	 
      	
                 (c)
      cancer vaccines which use any epitopes from EGF, TGF or Her
    1.

              
	 
      	 
      	 
      
	
                Confidential
      Information

              	 
      	
                Know-how
      and any other information owned or provided by one of the Parties, or by
      any Affiliates of one of the Parties. "Confidential Information" includes,
      without limitation, all inventions, discoveries, processes, materials,
      formulae, clinical development plans, data, ideas, financial information,
      legal, corporate, manufacture,
      marketing, product, research, personnel, customer, supplier and other
      non-public information, in whatever form or media, specifically identified
      as confidential prior to or at the time of its disclosure or disclosed
      orally and confirmed in writing as confidential within thirty (30) days of
      such oral  disclosure.

              
	 
      	 
      	 
      
	
                DAIICHI
      Field and Territory

              	 
      	
                The
      Field in the Territory.

              
	 
      	 
      	 
      
	
                DAIICHI
      Research and Development

              	 
      	
                Has
      the meaning given in Clause 4.2

              
	 
      	 
      	 
      
	
                Diligent
      Reasonable Efforts

              	 
      	
                Exerting
      such efforts and employing such resources (whether by itself or through
      sub-contractors or sub-licensees) as would normally be exerted or employed
      by a reasonable Third Party pharmaceutical company for a product of
      similar market potential at a similar stage of its product life, when
      utilizing sound and reasonable scientific, business and medical practice
      and judgment in order to develop the product in a timely manner and
      maximize the economic return from its
commercialisation.

              
	 
      	 
      	 
      
	
                EGF-R

              	 
      	
                Epidermal
      growth factor receptor.

              
	 
      	 
      	 
      
	
                Field

              	 
      	
                The
      treatment of cancer in humans.

              
	 
      	 
      	 
      
	
                Force
      Majeure Event

              	 
      	
                Has
      the meaning given in Clause 14.1.

              
	 
      	 
      	 
      
	
                Generic
      Drug

              	 
      	
                A
      drug containing TheraCIM h-R3 and that is bioequivalent to the Licensed
      Product with respect to pharmacokinetic and pharmacodynamic properties and
      that is required to meet the same pharmacopoeial requirements as the
      Licensed Product.

              
	 
      	 
      	 
      
	
                Gross
      Sales Value

              	 
      	
                Any
      and all amounts invoiced by DAIICHI from the sale of the Licensed Product
      to a Third Party in an arm's length transaction (or where the sale is not
      at arm's length, the price that would have been so invoiced and received
      if it had been at arm's length); provided that sales by DAIICHI to its
      Affiliates or sub-licensees shall not be considered a sale for the
      purposes of this definition unless there is no subsequent sale to a Person
      other than DAIICHI and its Affiliates in an arm's length
      transaction.

              
	 
      	 
      	 
      
	
                Indication(s)

              	 
      	
                Glioma
      and other indications which shall be considered and selected by DAIICHI
      for the Regulatory Applications in the Territory

              
	 
      	 
      	 
      
	
                Joint
      Development Team

              	 
      	
                A
      committee to be established, and operating, in accordance with the
      provisions of Clause 3.1

              
	 
      	 
      	 
      
	
                Know-how

              	 
      	
                The
      licensed Know-how and Arising Know-how.

              
	 
      	 
      	 
      
	
                Licensed
      Intellectual Property

              	 
      	
                Any
      and all of the Licensed Patent Rights and the Licensed
      Know-how.

              

      

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      
        	
                Licensed
      Know-how

              	 
      	
                Any
      and all trade secrets, know-how and technical, scientific, commercial and
      all other information in the possession of CIMYM or CIMAB in the Field as
      of the Commencement Date that relates to the Product and/or the inventions
      claimed in the Licensed Patent Rights, including the information further
      described in the attached Schedule 2, in each case
      to the extent that such information is relevant, related to, derived from
      or useful for the clinical development, registration, packaging,
      labelling, commercialisation, storage, use or sale of the Licensed Product
      within the Field in the Territory.

              
	 
      	 
      	 
      
	
                Licensed
      Patent Rights

              	 
      	
                Any
      and all patents and patent applications applied for or obtained by CIMYM
      or CIMAB in the Field and the Territory as of the Commencement Date
      relating to any Licensed Intellectual Property or the Product, together
      with any continuations, continuations in part, extensions, reissues,
      divisions, and any patents, supplementary protection certificates,
      conversion and similar rights that are based on or derive priority from
      the foregoing, as described in the attached Schedule
    1.

              
	 
      	 
      	 
      
	
                Licensed
      Product

              	 
      	
                The
      Product that is developed, commercialised or used by DAIICHI or its
      Affiliate under any of the Licensed Know-how or the Licensed Patent
      Rights.

              
	 
      	 
      	 
      
	
                Net
      Sales Value

              	 
      	
                The
      Gross Sales Value excluding (a) normal trade, cash and quantity discounts,
      allowances and credits, actually allowed and taken (including credit given
      for damaged, rejected or returned Licensed Product), (b) sales taxes, or
      other taxes, excluding withholding tax, duties and levies of a similar
      nature actually paid on the Licensed Product, (c) freight, postage,
      shipping, insurance and other transportation charges; provided always the
      total deductions pursuant to (a, b, and c) above shall not exceed 15% of
      the Gross Sales Value.

              
	 
      	 
      	 
      
	
                NHI
      price

              	 
      	
                Has
      the meaning given in Clause 8.2(a).

              
	 
      	 
      	 
      
	
                Parties

              	 
      	
                CIMYM,
      CIMAB and Daiichi, and “Party” shall mean any
      of them.

              
	 
      	 
      	 
      
	
                Patents

              	 
      	
                Any
      and all of the Licensed Patent Rights and the Arising
    Patents.

              
	 
      	 
      	 
      
	
                Person

              	 
      	
                Includes
      any individual, firm, company, corporation or other legal
      entity.

              
	 
      	 
      	 
      
	
                Product

              	 
      	
                Any
      product containing the humanised antibody to the EGF receptor, known
      scientifically as h-R3 and which has been given the INN "nimotuzumab" and
      otherwise referred to as TheraCIM h-R3.

              
	 
      	 
      	 
      
	
                QA
      Agreement

              	 
      	
                Any
      agreement between CIMAB, CIMYM, DAIICHI and/or DAIICHI's Affiliates
      relating to the quality assurance of the Licensed Product being supplied
      to DAIICHI under this Agreement or a Supply Agreement.

              
	 
      	 
      	 
      
	
                Re-examination
      Period

              	 
      	
                The
      period of 6 years following the date of the first regulatory approval of a
      pharmaceutical product in the Territory during which generic
      competition is not allowed.

              
	 
      	 
      	 
      
	
                Regulatory
      Application

              	 
      	
                Any
      and all applications that are necessary and appropriate to obtain a
      Regulatory Approval including, without limitation, all required documents,
      data and information concerning, filed or required to be filed or,
      otherwise submitted by DAIICHI to a Regulatory Authority in the
      Territory.

              

      

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      
        	
                Regulatory
      Approval

              	 
      	
                Any
      and all approvals, licenses, registrations or authorisations of any
      Regulatory Authority to DAIICHI that are necessary for the development,
      manufacture, packaging, labelling, use, storage, import, transport,
      marketing, distribution or sale of the Licensed Product in the
      Territory.

              
	 
      	 
      	 
      
	
                Regulatory
      Authority

              	 
      	
                The
      equivalents of the Ministry of Health, Labour and Welfare
      (Kosei-Rodo-Shos), the U.S. Food and Drug Administration and the
      Therapeutic Products Directorate of Health Canada or any successor agency
      thereto.

              
	 
      	 
      	 
      
	
                Research
      and Development Plan

              	 
      	
                Has
      the meaning given in Clause 4.1.

              
	 
      	 
      	 
      
	
                Safety
      Information Exchange Agreement

              	 
      	
                The
      agreement between the Parties stipulating necessary procedures and rules
      for handling and exchanging safety information in order to fulfill
      regulatory requirements appropriately at each Party and to take prompt
      safety measures for the Product.

              
	 
      	 
      	 
      
	
                Supply
      Agreement

              	 
      	
                Any
      agreement between CIMAB, CIMYM, DAIICHI and/or DAIICHI’s Affiliates under
      which CMIAB agrees to manufacture and supply CIMYM and/or DAIICHI’s
      Affiliates with the Licensed Product.

              
	 
      	 
      	 
      
	
                TTM
      Rate (Telegraphic Transfer Middle Rate)

              	 
      	
                Mean
      value of the TTS (Telegraphic Transfer Selling Rate) and the TTB
      (Telegraphic Transfer Buying Rate), which are rates of exchange of
      Japanese Yen for US Dollars.

              
	 
      	 
      	 
      
	
                Territory

              	 
      	
                Japan.

              
	 
      	 
      	 
      
	
                TheraCIM
      h-R3

              	 
      	
                A
      hurnanised antibody to the EGF receptor. known scientifically as h-R3 and
      which has been given the INN "nirnotuzumab''.

              
	 
      	 
      	 
      
	
                Third
      Party

              	 
      	
                A
      Person other than the Parties.

              
	 
      	 
      	 
      
	
                Valid
      Claim

              	 
      	
                A
      claim of a patent or patent application that has not expired or been held
      invalid or unenforceable by a court of competent jurisdiction in a final
      and non-appealable judgment.

              

      

    

    

    2   Grant
of Rights

     

    2.1   Licensed
Intellectual Property.   CIMYM hereby grants to DAIICHI,
subject to the provisions of this Agreement:

     

    (a) an
exclusive sub-license under the Licensed Intellectual Property to sell the
Licensed Product in the DAIICHI Field and Territory; and

    

    (b) an
exclusive sub-license, with a right to sub-sub-license to DAIICHI's Affiliates,
to use the Licensed Intellectual Property to research, develop, import, package,
label and use the Licensed Product in the DAIICHI Field and Territory;
and

    

    (c) the
right of DAIICHI to contract with any Third Party for the purpose of this
Agreement under the Licensed Intellectual Property to conduct research on and
develop the Licensed Product in the DAIICHI Field and
Territory.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    2.2   Sale of Licensed
Product.   For greater certainty, nothing in Clause 2.1
grants DAIICHI the right to sub-sub-license to its Affiliates the right to sell
the Licensed Product in the DAIICHI Field and Territory.

    

    2.3   License
to Manufacture.   Notwithstanding Clause 2.1(b), in the
case where the circumstances described in Clause 8.7 occur, CIMAB grants DAIICHI
a non-exclusive sub-license for the DAIICHI Field and Territory, to manufacture
by itself or to have manufactured by its Affiliates or a manufacturer nominated
by DAIICHI ("Third Party
Manufacturer"), the Licensed Product.

    

    2.4
  Arising
Intellectual Property.

     

    (a) Subject
to Clause 13.3(b), the Arising Know-how generated and disclosed by a Party to
the other Parties pursuant to Clause 7.1 during the term of this Agreement shall
be owned solely by the generating Party.

    

    (b) The
Arising Patents made by a Party during the term of this Agreement shall be owned
solely by such Party. The Arising Patents that claim an invention jointly
developed by the Parties shall be jointly owned by the Parties. The Parties
hereby agree that the identity of the inventor of all Arising Patents shall be
determined in accordance with Japanese patent law (or, if the jurisdiction in
which patent or other protection is being sought does not permit the application
of Japanese Patent law to identify the inventor, then in accordance with the
applicable law in that jurisdiction),

    

    (c) CIMYM
and CIMAB hereby grants and agrees to grant to DAIICHI, with a right to
sub-license to DAIICHI’s Affiliates, a non-exclusive, fully paid-up and
royalty-free, license under the Arising Intellectual Property, for the duration
of this Agreement (and any extension thereto) within DAIICHI Field and Territory
to research, develop, make, have made, import, use and otherwise deal in any and
all Licensed Product.

    

    (d) DAIICHI
hereby grants and agrees to grant to CIMYM/CIMAB, with a right to sub-license to
other Third Parties, a non-exclusive, fully paid-up and royalty-free, license
under the Arising Intellectual Property, for the duration of this Agreement (and
any extension thereto) within CIMYM/CIMAB Field and Territory to research,
develop, make, have made, import, use, sell and otherwise deal in any and all
Products.

    

    (e)
Notwithstanding Clauses 2.4(a), (c) and (d), in the event that any of the
Parties desire to be granted an exclusive license to another Party's Arising
Intellectual Property to research, develop, make, have made, import, use, sell
and otherwise deal in any and all Products, the applicable Parties will
negotiate in good faith to reach the terms and conditions for such
license.

    

    (f) If
DAIICHI develops an improvement of the Licensed Intellectual Property and an
Arising Patent claims such improvement, DAIICHI undertakes not to assert such
Arising Patent against CIMYM/ClMAB, its Affiliates, successors, assignees or
licensees for manufacturing, using or selling the Product that otherwise would
infringe such Arising Patent.

    

    2.5   Applicable Patent
Law. The
determination of whether Arising Intellectual Property is conceived, discovered,
developed or otherwise made by a Party for the purpose of inventorship
(including patent or other intellectual property rights), shall, for purposes of
this Agreement, be made in accordance with Japanese patent law (or, if the
jurisdiction in which patent or other protection is being sought does not permit
the application of Japanese Patent law to identify the inventor, then ill
accordance with the applicable law in that jurisdiction).

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    2.6   Formal
Licenses. If
requested by any of the Parties and at the requesting Party's administrative
cost, the Parties shall execute such formal licenses as may be necessary or
appropriate for registration with Japan Patent Office and other relevant
authorities in the Territory. In the event of any conflict in meaning between
any such license and the provisions of this Agreement, the provisions of this
Agreement shall prevail. The Parties shall use reasonable endeavours to ensure
that, to the extent permitted by relevant authorities, this Agreement shall not
form part of any public record.

    

    2.7   Reservation of
Rights within Field and Territory.   For the avoidance of
doubt, CIMYM reserves the right for itself and its sub-licensees and assigns to
use the Product and the Licensed Intellectual Property in the DAIICHI Field and
Territory with the prior written consent of DAIICHI (a) for the purposes of
research; and/or (b) for the purposes of development (including clinical trials)
of the Products with a view to filing Regulatory Applications and obtaining
Regulatory Approval for such Products in the CIMYM/CIMAB Field and Territory. If
CIMYM wishes to conduct research or development activities in the DAIICHI Field
and Territory in accordance with the provisions of this Clause 2.7, CIMYM will
so inform DAIICHI and give DAIICHI a first opportunity to propose terms for an
agreement with CIMYM under which

    DAIICHI
would assist CIMYM with such activities at the cost of CIMYM.

    

    2.8   No Other
License.  It is acknowledged and agreed that no license is
granted by CIMYM to DAIICHI other than the sub-license(s) expressly granted by
the provisions of this Clause 2. Without prejudice to the generality of the
foregoing, CIMYM reserves all rights under the Licensed Intellectual Property in
the CIMYM/CIMAB Field and Territory.

    

    2.9   Acknowledgement
by CIMAB.   CIMAB acknowledges and agrees that CIMYM has
been granted the necessary rights and licenses to enable it to grant the
licenses and sub-licenses referred to in this Clause 2.

    

    3   Join
Development Team

    

    3.1   Formation. Within thirty (30) days
after the Commencement Date, CIMYM, CIMAB and DAIICHI shall establish a joint
development team in order to exchange worldwide development plans and
information created by each Party and their sub-licensees regarding any and all
Products ("Joint Development
Team"), by each Party designating its initial members to serve on the
Joint Development Team and notifying each other Party of its dates of
availability for the first meeting of the Joint Development Team. The Joint
Development Team shall consist of not more than three (3) representatives
designated by each Party. Each representative shall have relevant and
appropriate expertise in order to exchange development plans and information
regarding the Products. If a representative of a Party is unable to attend a
meeting of the Joint Development Team, such Party may designate an alternate to
attend such meeting. In addition, each Party may, at its discretion, invite a
reasonable number of other employees, consultants or scientific advisors to
attend the meetings of the Joint Development Team, provided that such invitees
are bound by appropriate confidentiality obligations. Each Party may change one
or all of its representatives to the Joint Development Team at any time upon
notice to the other Party. DAIICHI shall have final decision-making authority
with respect to the Licensed Product in the DAIICHI Field and Territory. DAIICHI
may attend joint development meetings between CIMYM, CIMAB and other
sub-licensees, if approved in writing by CIMYM, CIMAB and by the other
sub-licensees.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    3.2   Meetings.   During
the term of this Agreement, unless otherwise agreed in writing among the
Parties, the Joint Development Team shall meet quarterly in person or by
teleconference and at such other times as the Parties may agree. The first
meeting of the Joint Development Team shall be held as soon as reasonably
practicable, but in no event later than ninety (90) days after the Commencement
Date. Meetings shall be held at such place or places as are mutually agreed or
by teleconference or videoconference; provided, however, that there shall be at
least one face-to-face meeting per calendar year.

    

    3.3   Responsibilities.   The
Joint Development Team shall have the responsibility to:

    

    (a)
review and update the Research and Development Plan in accordance with Clause
4.1;

    

    (b)
review the overall research and development strategy for the Licensed Product in
the DAIICHI Field and Territory (including, without limitation, setting criteria
for progression of the Licensed Product to the next stage of development under
the Research and Development Plan);

    

    (c)
review the modifications to the Research and Development Plan;

    

    (d)
facilitate the disclosure of Arising Intellectual Property and other information
between the Parties for purposes of conducting the Research and Development
Plan;

    

    (e)
regularly assess the progress of Parties and other sub-licensees in the conduct
of the Research and Development Plan.

    

    For the
avoidance of doubt the Joint Development Team shall not have any role or
responsibility in relation to determining whether DAIICHI, CIMYM or CIMAB has
complied with its obligations to the other Parties under this
Agreement.

    

    3.4   Consultation.

    

    (a) In
the event that CIMYM objects to the action relating to DAIICHI Research and
Development activities proposed to be taken by DAIICHI, on the basis that it
would prejudice CIMYM's, CIMAB's or any of their licensees or sub-licensees'
rights to the Product, then DAIICHI agrees to negotiate in good faith with CIMYM
to cease such activity or to pursue a different avenue which would not be
prejudicial to CIMYM, CIMAB or their licensees or sub-licensees.

    

    (b) In
the event that DAIICHI objects to the action relating to research and
development activities proposed to be taken by CIMYM, CIMAB and/or their
licensees or sub-licensees, on the basis that it would prejudice DAIICHI's
rights to the Licensed Product in the DAIICHI Field and Territory, then CIMYM
and/or CIMAB agree to negotiate in good faith with DAIICHI to cease such
activity or to pursue a different

    avenue
which would not be prejudicial to DAIICHI.

    

    4   Research
and Development

    

    4.1   Research and
Development Plan.   Within sixty (60) days of the
Commencement Date, DAIICHI shall submit a non-binding written research and
development plan for the Licensed Product in the DAIICHI Field and Territory
("Research and Development
Plan") to the Joint Development Team, that expands upon the initial
development plan set out in Schedule
3 and that will describe and provide a timeline for:

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    (a) all
development activities for the Licensed Product in the DAIICHI Field and
Territory, addressing each phase of development and providing detailed
information on the activities to be conducted in the next 12-month
period;

    

    (b)
clinical and registration strategy, with a view to expediting Regulatory
Approval; and

    

    (c) sales
forecast of the Licensed Product for the five (5) year period after the first
commercial sale of the Licensed Product in the DAIICHI Field and
Territory.

    

    The Joint
Development Team shall review the progress of the Research and Development Plan
at the meetings described in Clause 3.2 of this Agreement.

    

    4.2   Research and
Development Activities.   DAIICHI shall be responsible for
the research and development, including non-clinical and clinical studies ("DAIICHI Research and
Development") in accordance with the Research and Development Plan. Such
DAIICHI Research and Development shall be carried out under the oversight and
management of DAIICHI and in accordance with the provisions of this
Agreement.

    

    4.3   Research and
Development Costs.   DAIICHI shall bear all costs
associated with DAIICHI Research and Development, including costs incurred in
the preparation and execution of the Research and Development Plan. If C1MYM
and/or CIMAB agree with DAIICHI to conduct work at DAIICHI's request as part of
the Research and Development Plan (which may include advice given to the Joint
Development Team), payment of CIMYM and/or CIMAB’s costs of conducting such work
shall be discussed between the Parties in accordance with each Parties'
contribution on such work.

    

    4.4   Exchange of
Information.   It is CIMYM's intention to grant
sub-licensees of its rights to commercialise the Product in the CIMYM/CIMAB
Field and Territory, and to facilitate the expeditious DAIICHI Research and
Development of the Licensed Product in the DAIICHI Field and Territory.
Accordingly, each of the Parties, or CIMYM's and/or CIMAB's licensee(s) or
sub-licensee(s), may generate data in relation to the Product that is useful to
the other Parties in connection with their research or development of the
Product. To facilitate such research and development, each Party shall, after
appropriate confidentiality agreements are entered into and subject to
pre-existing agreements, disclose and provide from time to time to the other
Parties with information related to: (a) all Arising Intellectual Property, (b)
worldwide research and development plans for the Product carried out by each
Party and/or its licensee(s) or sub-licensee(s), (c) the summary and result of
research and development of the Product carried out by each Party and/or its
licensee(s) or sub-licensee(s), and (d) all notices and other correspondence
between the Parties, its Affiliates, its licensee(s) and/or its sub-licensee(s)
and any Regulatory Authority related to the Product. DAIICHI agrees not to use
information provided by CIMYM or CIMAB and their respective licensees for any
other purpose than the development and commercialization of the Licensed Product
under this Agreement.

    

    4.5   Exchange of the
Safety Information.   The Parties shall provide each other
with necessary information and data relating to adverse drug reactions, adverse
events and serious adverse events in accordance with the Safety Information
Exchange Agreement. Such agreement shall be concluded three (3) months prior to
the start of phase I clinical trial for the Licensed Product in the DAIICHI
Field and Territory.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    4.6   Regulatory
Applications.   DAIICHI will submit Regulatory
Applications for the Regulatory Approval to market the Licensed Product in the
Territory. The applications will be based on the data generated in clinical
trials undertaken by DAIICHI, CIMAB, CIMYM and/or their licensee(s) or
sub-licensee(s). DAIICHI will provide CIMYM with all notices and other
correspondence with Regulatory Authorities relating to the Regulatory
Applications in accordance with Clause 4.4.

    

    4.7  Response to
Regulatory Authorities.   DAIICHI will submit Regulatory
Applications for the Regulatory Approval to market the Licensed Product in the
Territory. The applications will be based on the data generated in clinical
trials undertaken by DAIICHI, CIMAB, CIMYM and/or their licensee(s) or
sub-licensee(s). DAIICHI will provide CIMYM with all notices and other
correspondence with Regulatory Authorities relating to the Regulatory
Applications in accordance with Clause 4.4.

    

    4.8   Ownership of
Regulatory Approvals.   Subject to Clause 13.3(b), all
Regulatory Approvals issued pursuant to the Regulatory Applications submitted by
DAIICHI in the DAIICHI Field and Territory will be owned by
DAIICHI.

    

    5   Sales
Promotion / Marketing

    

    5.1   Sales
Promotion.   DAIICHI shall use its commercially reasonable
efforts to promote at its own costs and on its own responsibility, sales of the
Licensed Product in the DAIICHI Field and Territory.

    

    6   Non-Competition

    

    6.1   During
the term of this Agreement, DAIICHI shall not sell or promote any Competitive
Product in the Territory for anti-cancer treatment.

    

    7   Know-how
and Confidential Information

    

    7.1   Provision of
Know-how.

    

    (a) After
the Commencement Date and from time to time during the term of this Agreement,
upon DAIICHI’s reasonable written request, CIMYM shall supply DAIICHI with all
Licensed Know-how in its possession that is relevant to, derived from or useful
for the development, registration, commercialisation, use or sale of the
Licensed Product within the DAIICHI Field and Territory. It is expressly
understood that prior to the Commencement Date, CIMYM has already disclosed to
DAIICHI and DAIICHI has received from CIMYM part of the Licensed Know-how under
the confidentiality agreement dated December 7, 2004 (the “Confidentiality Agreement”).
The Parties acknowledge that this Agreement applies to the disclosure of
Licensed Know-how that was made under the Confidentiality Agreement and prevails
over the Confidentiality Agreement. The Licensed Know-how shall be subject to
the confidentiality provisions of Clause 7.2.

    

    (b) Each
of the Parties shall provide the other Parties with the Arising Know-how in
their possession that is relevant to, derived from or useful for the
development, registration, commercialisation, use or sale of the Product within
each Party’s field and territory, from time to time.

    

    7.2   Confidentiality
Obligations.   Each Party (“Receiving Party”)
undertakes:

    

    (a) to
maintain as secret and confidential all Confidential Information obtained
directly or indirectly from the other Party (“Disclosing Party”) in the
course of or in anticipation of this Agreement and to respect the Disclosing
Party’s rights therein,

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    (b) to
use the same exclusivity for the purposes except as expressly licensed hereby
and strictly in accordance with the provisions of this Agreement,
and

    

    (c)
subject to the provisions of Clause 7.5, to disclose the same only to those of
its Affiliates, employees, contractors, licensees and sub-licensees pursuant to
this Agreement (if any) to whom and to the extent that such disclosure is
reasonably necessary for the purposes of this Agreement.

    

    7.3   Exceptions to
Obligations. The provisions of Clause
7.2 shall not apply to Confidential Information which the Receiving Party can
demonstrate:

    

    (a) was,
prior to its receipt by the Receiving Party from the Disclosing Party, in the
possession of the Receiving Party and at its free disposal;

    

    (b) is
subsequently disclosed to the Receiving Party without any obligations of
confidentiality by a Third Party who was not under a duty of confidentiality and
did not derive it directly or indirectly from the Disclosing Party;
or

    

    (c) is or
becomes generally available to the public through no act or default of the
Receiving Party or its agents, employees, Affiliates or
sub-licensees.

    

    7.4   Disclosure to
Court, etc.   If the Receiving Party or its Affiliates,
employees, contractors, licensees and sub-licensees to whom Confidential
Information is disclosed are required to disclose Confidential Information to
the courts of any competent jurisdiction, or to any government regulatory agency
or financial authority, such disclosure shall not be a breach of Clause 7.2,
provided that the Receiving Party or its Affiliates, employees, contractors,
licensees and
sub-licensees to whom Confidential Information is disclosed shall (a) inform the
Disclosing Party as soon as is reasonably practicable and shall only disclose
Confidential Information to the extent so required, and (b) allow the Disclosing
Party to seek to persuade the court, agency or authority to have the information
treated in a confidential manner, where this is possible under the court, agency
or authority's procedures.

    

    7.5   Disclosure to
Employees, etc. The Receiving Party
shall ensure that all of its Affiliates, employees, contractors, consultants,
advisers, licensees and sub-licensees pursuant to this Agreement (if any) who
have access to any of the Disclosing Party's Confidential Information to which
Clause 7.2 applies, shall be made aware of and subject to these obligations and
shall have entered into written undertakings of confidentiality at least as
restrictive as Clauses 7.2 and 7.3 prior to receiving the Disclosing Party's
Confidential Information.

    

    7.6   Ownership of
Confidential Information. Subject to Clause
2.4(a), all Confidential Information disclosed by the Disclosing Party shall, as
between the Parties, remain the sole and exclusive property of the Disclosing
Party including without limitation:

    

    (a) all
ideas, concepts, information, trade secrets, know-how, business strategies and
methods relating to the Confidential Information;

    

    (b) all
physical material containing, bearing, or embodying any Confidential Information
in human or machine readable form. including, without limitation, all documents,
agreements, diagrams, charts, graphs, computer programs, computer diskettes, and
computer files; and

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    (c) all
proprietary and intellectual property rights in the Confidential Information,
regardless of whether these items were created, generated, developed, produced
or prepared by or on behalf of the Disclosing Party, and regardless of whether
these items came into being before or after the date hereof.

    

    7.7   Return of
Confidential Information.   Upon the request of the
Disclosing Party, the Receiving Party will promptly return to the Disclosing
Party, or at the Disclosing Party's election, destroy all Confidential
Information of the Disclosing Party in its possession or in the possession of
its representatives. The Receiving Party shall use reasonable efforts to cause
its representatives and any other Party acting under its direction or control to
return all materials containing Confidential Information; provided always
DAIICHI may retain a copy of all Confidential Information disclosed to DAIICHI
pursuant to this Agreement for the duration of this Agreement and for archival
purposes.

    

    8  Manufacturing
and Supply

    

    8.1   Clinical
Supply.  CIMAB or CIMAB's Contract Manufacturers shall supply
to CIMYM and CIMYM shall supply to DAIICHI and/or its Affiliates, and DAIICHI
and/or its Affiliates shall purchase from CIMYM for its own use and that of its
Affiliates one hundred percent (100%) of DAIICHI’s unit requirements of the
Licensed Product in agreed form for the purpose of all non-clinical and clinical
studies ("Studies") and post-marketing clinical trials ("PMS Studies"). Such
requirements shall be supplied to DAIICHI in accordance with the following terms
and conditions:

    

    (a) In
respect of DAIICHI’s requirements for non-clinical studies in accordance with
the Research and Development Plan, whether for the purposes of seeking
Regulatory Approvals or not, CIMYM shall provide to DAIICHI, upon request by
DAIICHI, with any quantity of the Licensed Product in agreed form that is
necessary for DAIICHI's requirements at US$* per gram of TheraCIM h-R3. Payment
will be made by DAIICHI within sixty (60) days after receiving the Licensed
Product from CIMYM.

    

    (b) In
respect of DAIICHI's requirements for the clinical studies in accordance with
the Research and Development Plan, whether for the purposes of seeking
Regulatory Approvals or not, CIMYM shall provide to DAIICHI with such Licensed
Product in agreed format US$* per gram of TheraCIM h-R3, under the terms and
conditions of the Supply Agreement as set forth in Clause 8.5. Payment will be
made by DAIICHI within sixty (60) days after receiving the Licensed Product from
CIMYM.

    

    (c) For
all other supply for the PMS Studies, CIMYM shall sell such Licensed Product in
agreed form to DAIICHI under the terms and conditions of the Supply Agreement as
set forth in Clause 8.5.

    

    8.2   Commercial
Supply.   CIMAB or CIMAB's Contract Manufacturers shall
supply to CIMYM and CIMYM shall supply to DAIICHI and/or its Affiliates, and
DAIICHI and/or its Affiliates shall purchase from CIMYM one hundred percent
(100%) of DAIICHI’s unit requirements of the Licensed Product in agreed form for
the purpose of all commercial sales in accordance with the terms of this
Agreement and the Supply Agreement. CIMYM shall be the exclusive supplier of the
Licensed Product to DAIICHI or its Affiliates.

    

    CIMAB
shall prepare one or more of CIMAB's Contract Manufacturer(s), at its cost and
responsibility, as a back-up source for any quantity of the Licensed Product
that is necessary for DAIICHI's requirements, including the Licensed Product for
the Studies and PMS Studies under Clause 8.1, in the event of supply shortage by
CIMAB as set forth in Clause 8.6. To prepare CIMAB's Contract Manufacturer(s),
CIMAB shall ensure that CIMAB's Contract Manufacturer(s) implement tests
including, but not limited to, the bioequivalence test and comparability lest,
and DAIICHI shall have the right to audit CIMAB's Contract manufacturer for
compliance with applicable regulatory laws in the Territory.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    The
supply price (C.I.P by air) of the Licensed Product to DAIICHI for commercial
sales in the Territory shall be as follows:

    

    (a) In
the event that the National Health Insurance price ("NHI price") of the Licensed
Product as of the first commercial sale in the Territory is JPY * or more per
200mg of TheraCIM h-R3, the supply price shall be * percent (*%) of the Net
Sales Value of the Licensed Product in all dosage forms, during the term of the
Re-examination Period for the Licensed Product in the Territory. After the
Re-examination period, the supply price shall be reduced to * percent (*%) until
*th anniversary of the first commercial sale of the Licensed Product in the
Territory.

    

    (b) In
the event that the NHI price of the Licensed Product as of the first commercial
sale in the Territory is JPY * or more but less than JPY * per 200mg of
TheraCIM h-R3, the supply price shall be * percent (*%) of the Net Sales Value
of the Licensed Product in all dosage forms, during the term of the
Re-examination Period for the Licensed Product in the Territory. After the
Re-examination period, the supply price shall be reduced to * percent (*%)
until * anniversary of the first commercial sale of the Licensed Product in
the Territory.

    

    (c) The
supply price after * anniversary of the first commercial sale of the
Licensed Product in the Territory shall be separately negotiated in good faith
by the Parties prior to the expiration of the initial term of this
Agreement.

    

    (d) In
the event that the NHI price of the Licensed Product as of the first commercial
sale in the Territory is less than JPY * per 200mg of TheraCIM h-R3, the Parties
shall separately negotiate in good faith on the supply price.

    

    (e) In
the event that the NHI Price of the Licensed Product after launch is reduced
severely, the Parties shall separately negotiate in good faith on the supply
price.

    

    (f) In
the event that any Generic Drug of the Licensed Product is launched in the
Territory, the Parties shall separately negotiate in good faith a reduction to
the supply price.

    

    
      
        
          
            
              
                
                  
                    	 
      	 	
                            Re-examination

                            Period

                          	 	 	
                            thereafter and 

                            until *th

                            anniversary

                          	 	
                            thereafter

                          
	
                            JPY
      * <= NHI price

                          	 	 	*	%	 	 	*	%	 
      
	
                            JPY
      * <= NHI price < JPY *

                          	 	 	*	%	 	 	*	%  	
                            separately
      discussed

                          
	
                            NHI
      price < JPY *

                          	 	
                            separately
      discussed

                          	 	 
      

                  

                

              

            

          

        

      

    

     

    Payment
shall be made by DAIICHI within sixty (60) days after the date of receiving the
Licensed Product from CIMYM.

     

    8.3   Quality.   DAIICHI
shall ensure that all Licensed Product marketed by it is of satisfactory quality
and complies with all applicable laws and regulations in the
Territory.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    8.4   Specifications.   CIMAB
undertakes that all Licensed Product supplied to CIMYM (and thereafter to
DAIICHI) will be manufactured in accordance with mutually agreed upon
specifications (inclusive of specifications in an approved marketing
authorization), the current rules of Good Manufacturing Practices of the
relevant Regulatory Authorities in the Territory and the countries of
manufacture of the Licensed Product, and will not be adulterated or misbranded
under applicable laws, regulations or guidelines, and that the manufacturer will
have in force all necessary regulatory approvals for the manufacture of the
Licensed Product in accordance with such specifications for the purposes of
supply and use of the Licensed Product in the Territory, and will be in good
standing with all regulatory authorities.

     

    8.5   Supply
Agreement.   The Licensed Product for clinical studies,
the PMS Studies and commercial sales shall be supplied by CIMAB or CIMAB's
Contract Manufacturer(s) to CIMYM and by CIMYM to DAIICHI or its Affiliate
pursuant to the terms of a separate Supply Agreement and a QA Agreement.
DAIICHI, DAIICHI's Affiliates, CIMYM and CIMAB shall use good faith efforts to
negotiate and enter into: (a) a Supply Agreement and a QA Agreement for the
clinical studies promptly after the Commencement Date; and (b) a Supply
Agreement and a QA Agreement for the PMS Studies and commercial purposes at
least six (6) months after the submission of a Regulatory Application for the
Licensed Product in the Territory. The Supply Agreements shall contain forecast
procedures, permitted variances from forecasted amounts, order and delivery
times, shipping terms, quality control and quality assurance procedures, audits,
yield ratios, maintenance of inventory, procedures and remedies for rejection of
non-conforming product, record retention, compliance with laws, and other
customary provisions.
The terms of the Supply Agreement shall be consistent with the provisions of
this Clause 8, unless otherwise agreed in writing among the
Parties.

    

    8.6    Supply
Shortage.

    

    (a) CIMYM
shall notify DAIICHI immediately upon becoming aware that CIMAB or CIMAB's
Contract Manufacturer is unable to supply CIMYM the quantity of the Licensed
Product ordered by DAIICHI. In such circumstances, CIMYM and CIMAB shall use all
best endeavours to remedy such shortage.

    

    (b) In
the event CIMAB is unable to supply CIMYM (and therefore DAIICHI's) requirements
of the Licensed Product for any reason, CIMAB shall allocate an amount of the
Product in its inventory so that DAIICHI receives at least its proportionate
shore (as between CIMYM's other licensees globally) of such available supplies,
as determined from reasonable forecasts and orders therefore as more
specifically set forth in the Supply Agreement.

    

    8.7   Right to Manufacture for the
Territory.

    

    (a) In
the event that (i) CIMAB or CIMAB's Contract Manufacturer is unable to
manufacture the Licensed Product which meets with the specifications accepted by
the Japanese Regulatory Authority or by the terms of any relevant Registration
Approval, or (ii) CIMAB or CIMAB's Contract Manufacturers is or are unable to
supply CIMYM and therefore CIMYM is unable to supply DAIICHI with requirements
of the Licensed Product for three consecutive months twice in any given two year
period and in such quantities in accordance with reasonable forecasts as agreed
by the Parties, DAIICHI shall have the right to manufacture by itself or its
Affiliate, or have manufactured by a Third Party Manufacturer, one hundred
percent (100%) of its own requirements for Studies, commercial sales and PMS
Studies for the Licensed Product, in accordance with the provisions of Clause
8.7(b). Detailed terms and conditions of such grant of manufacture right shall
be separately negotiated and determined among the Parties.

    

    (b) To
enable DAIICHI to have the Licensed Product manufactured for it in accordance
with Clause 8.7(a), the Parties shall, if the events described in Clause 8.6(a)
occur, make arrangements for the transfer of Licensed Know-how relevant to or
useful for the manufacture of the Licensed Product to DAIICHI or its Affiliate,
or a Third Party Manufacturer so long as the Third Party Manufacturer executes
confidentiality agreements with the Parties on terms and conditions at least as
restrictive as those under this
Agreement. CIMAB shall fully cooperate with and shall take all commercially
reasonable actions with DAIICHI, its Affiliate or such Third Party Manufacturer,
to provide DAIICHI with such documentation, Know-how and technical assistance,
without charge to DAIICHI.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    9   Payments

    

    9.1   Initial
Payment.   DAIICHI shall pay to CIMYM a non-refundable,
non-creditable upfront payment of US$14,500,000 within thirty (30) days of
receipt of an invoice after the Commencement Date.

    

    9.2   Milestone
Payment.   Upon the occurrence of each of the following
events, DAIICHI shall pay to CIMYM the following non-refundable, non-creditable
milestone payments, within thirty (30) days from the date of such
events:

    

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            	
                                    License
      Fees Payable Upon the

                                    Achievement
      of Milestones:

                                  	 	 
      	 	 	 
	
                                    Glioma
      (Adult)

                                  	 	
                                    Filing
      of Glioma NDA in the Territory

                                  	 	US$	*	 
	 
      	 	
                                    Approval
      of Glioma NDA in the Territory

                                  	 	US$	*	 
	 
      	 	 
      	 	 	 	 
	
                                    Indication
      #2

                                  	 	
                                    Initiation
      of Pivotal Indication #2 study in the Territory

                                  	 	US$	*	 
	 
      	 	
                                    Filing
      of Indication #2 NDA in the Territory

                                  	 	US$	*	 
	 
      	 	
                                    Approval
      of Indication #2 NDA in the Territory

                                  	 	US$	*	 
	 
      	 	 
      	 	 	 	 
	
                                    Indication
      #3

                                  	 	
                                    Initiation
      of Pivotal Indication #3 study in the Territory

                                  	 	US$	*	 
	 
      	 	
                                    Filing
      of Indication #3 NDA in the Territory

                                  	 	US$	*	 
	 
      	 	
                                    Approval
      of Indication #3 NDA in the Territory

                                  	 	US$	*	 
	 
      	 	 
      	 	 	 	 
	
                                    Indication
      #4

                                  	 	
                                    Initiation
      of Pivotal Indication #4 study in the Territory

                                  	 	US$	*	 
	 
      	 	
                                    Filing
      of Indication #4 NDA in the Territory

                                  	 	US$	*	 
	 
      	 	
                                    Approval
      of Indication #4 NDA in the Territory

                                  	 	US$	*	 
	 
      	 	 
      	 	 	 	 
	 
      	 	
                                    Upon
      reaching JPY * of Net Sales Value in a calendar year.

                                  	 	US$	*	 

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

    

    9.3   Payment
Terms.   All sums due under this Agreement, including the
supply price of the Licensed Product pursuant to Clauses 8.1 and
8.2:

    

    (a) shall
be paid in US dollars (or such other currency as CIMYM and DAIICHI may agree in
writing) and, in the case of Net Sales Value received by DAIICHI in a currency
other than US dollars, the amount shall be calculated in the other currency and
then converted into equivalent US dollars at the TTM Rate for US dollars as
quoted by Bank of Tokyo-Mitsubishi UFJ in Tokyo, as applicable, as at the close
of business on the last business day of the quarterly period with respect to
which the payment is made;

    

    (b) shall
be paid by the due date, failing which CIMYM may charge interest on any
outstanding amount on a daily basis at a prevailing US prime rate plus eight
percent (8%) then in force published by the Wall Street Journal compounded
monthly. By way of example, if the Wall Street Journal US prime rate is five
percent (5%), CIMYM may charge thirteen percent (13%) per annual on such
outstanding amount.

    

    9.4   Accounting
Statements.   During the term of this Agreement following
the first commercial sale of the Licensed Product in the Territory, DAIICHI
shall send to CIMYM, within ninety (90) days of the end of each fiscal year, a
statement selling out, in respect of the Territory in which the Licensed Product
is sold, the types of the Licensed Product sold, the quantity of each type sold,
the Gross Sales Value itemizing deductions and allowance actually taken, and the
Net Sales Value in respect of each type, expressed both in local currency and US
Dollars and showing the conversion rates used during the period to which the
statement relates.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    9.5   Records.

    

    (a)
DAIICHI shall keep at its normal place of business detailed and up to date
records and accounts relevant to the statement described in Clause 9.4 showing
the quantity, description, Gross Sales Value and Net Sales Value of the Licensed
Product, all source documents and other records corresponding to Gross Sales
Value, Net Sales Value or any deductions from Gross Sales Value and from Net
Sales Value in respect of the Licensed Product in sufficient detail to ascertain
the payments due under this Agreement for the three (3) year period after the
relevant statement is sent to ClMYM.

    

    (b)
During the term of this Agreement, DAIICHI and its Affiliates shall make such
records and accounts available, on reasonable notice, for inspection during
business hours by an independent chartered accountant nominated by CIMYM for the
purpose of verifying the accuracy of any statement or report given by DAIICHI to
CIMYM under this Agreement. Such inspection shall be limited to no more than one
(1) time each twelve (12) month period. The accountant shall be required to keep
confidential all information learned during any such inspection, and to disclose
to CIMYM only such details as may be necessary to report on the accuracy of
DAIICHI's or its Affiliates statement or report. CIMYM shall be responsible for
the accountant's fees and expenses unless the accountant certifies that there is
an inaccuracy of more than five percent (5%) in any accounting statement, in
which case DAIICHI and its Affiliates shall pay the accountant's fees and
expenses in respect of that inspection. If the inspection shows that DAIICHI or
its Affiliates owes a payment to CIMYM under this Agreement, DAIICHI shall
promptly make such payment.

    

    (c)
DAIICHI shall ensure that CIMYM has the same rights as those set out in this
Clause 9.5 in respect of any Affiliate of DAIICHI that is participating in the
execution of DAIICHI's rights and obligations under this Agreement.

    

    9.6   Taxes.   A
Party may deduct from any amounts it is required to pay pursuant to this
Agreement an amount equal to that withheld for or due on account of any taxes
(other than taxes imposed on or measured by net income) or similar governmental
charge imposed by a jurisdiction other than the United States ("Withholding Taxes"). At the
receiving Party's request, the paying Party shall provide the receiving Party a
certificate evidencing payment of any Withholding Taxes hereunder and shall
reasonably assist the receiving Party, at the receiving Party's expense, to
obtain the benefit of any applicable tax treaty.

    

    10   Diligence

    

    10.1   Diligent and
Reasonable Efforts.   DAIICHI shall use Diligent and
Reasonable Efforts to develop and commercially exploit the Licensed Product to
the maximum extent throughout the Territory. Without limiting DAIICHI's
obligations under the previous sentence of this Clause 10.1, DAIICHI shall
develop and commercially exploit the Licensed Product in accordance with the
Research and Development Plan.

    

    11   Intellectual
Property

    

    11.1   Obtain and
Maintain the Licensed Patent Rights.   CIMYM/CIMAB shall
be responsible, at CIMYM/CIMAB's cost and expense, for seeking to obtain valid
patents pursuant to each of the Licensed Patent Rights in the Territory, and
shall:

    

    (a)
diligently seek to obtain valid patents pursuant to each of the Licensed Patent
Rights in the Territory; and

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    (b) pay
all prosecution, maintenance, and renewal fees in respect or the Licensed Patent
Rights as and when due.

    

    CIMYM/CIMAB
shall not abandon any Licensed Patent Rights within DAIICHI's Field and
Territory.

    

    11.2   Obtain and
Maintain the Arising Patents.   In relation to the filing
and maintenance of each Party's
Arising Patents, each Party shall, at its own cost and expenses:

    

    (a)
diligently seek to obtain valid patents in the names of the inventing parties,
as specified in Clause 2.4(b), in the each territory: and

    

    (b) pay
all prosecution, maintenance, and renewal fees in respect of the Arising Patents
as and when due,

    

    provided
that if each Party ("Abandoning
Party") wishes to abandon or not maintain any such application or not to
maintain any such Party's Arising Patent (or to cease funding such application
or patent) (collectively, "Abandoned Patents") within
the DAIICHI Field and Territory, such Abandoning Party shall give three (3)
months' prior written notice to the other Party and on the expiry of such notice
period with respect to such Abandoned Patents in the DAIICHI Field and
Territory, the Abandoning Party shall promptly assign all rights and interest in
such Abandoned Patents or patent applications in question to be assigned to the
other Parry and the Abandoning Party shall have no continuing rights under such
Arising Patents in the DAIICHI Field and Territory.

    

    In the
event that an Arising Patent is jointly owned by the Parties, responsibility and
cost of prosecuting such Arising Patent shall be allocated as
follows:

    

    (c) Prosecution.
CIMYM/CIMAB shall prepare, file, prosecute and maintain the appropriate filings
in respect of any jointly owned Arising Patents in the United States and in such
other jurisdictions as CIMYM/CIMAB determines jointly with DAIICHI, acting
reasonably, that are necessary in order to protect CIMYM/CIMAB's and DAIICHI's
rights in such Arising Patent. CIMYM/CIMAB shall ensure that all filings are
filed in the name of CIMYM/CIMAB and DAIICHI as co-owners.

    

    (d) Expenses. The Parties
hereby agree that all out-of-pocket costs and expenses (including attorneys'
fees and government filing fees) incurred by CIMYM/CIMAB to prepare, file,
prosecute and maintain the appropriate filings to protect the Parties' rights in
any jointly owned Arising Patent ("Patent Expenses") will be
shared equally by the Parties to be named on such Arising Patent. CIMYM/CIMAB
shall submit invoices (including all relevant receipts) for the appropriate
amount of such Patent Expenses to DAIICHI on a quarterly basis. Each invoice
shall be paid by DAI1CHI within thirty (30) days of the receipt of such invoice
from CIMYM/CIMAB.

    

    (e) Disclaimer. Either
Party may, at any time, disclaim its interest in such jointly owned Arising
Patent and elect to cease to bear its share of the Patent Expenses in respect of
such jointly owned Arising Patent by providing notice of such election ("Disclaimer Notice") to the
other Party; provided, however, the disclaiming Party shall remain liable for
its share of all Patent Expenses incurred or committed to through the date the
non-disclaiming party receives the Disclaimer Notice. In the event that a
Disclaimer Notice is delivered by either Party: (A) the disclaiming Party shall
promptly assign its ownership interest in such Arising Patent to the
non-disclaiming Party without consideration; (B) except as set forth in Clause
11.2(d) above, as of the date of the receipt of such Disclaimer Notice by the
non-disclaiming Party, the disclaiming Party shall no longer be responsible for
its share of the Patent Expenses in respect of such Arising Patent; (C) except
as set forth in Clause 11.2(d) above, as of the date of the receipt of such
Disclaimer Notice by the non-disclaiming Party, the non-disclaiming Party shall
be solely responsible for all Patent Expenses; and (D) except as expressly set
forth in Clauses 2.4(c) and 2.4(d) above, the disclaiming Party shall have no
further rights to such Arising Patent.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    11.3   Infringement of
Licensed Patent Rights.   Each Party shall inform the
other Party promptly if it becomes aware of any alleged infringement or
potential infringement of any of the Licensed Patent Rights or CIMYM/CIMAB's
Arising Patents in the DAIICHI Field and Territory. The Parties shall consult
each other on the best way to respond to such infringement. CIMYM shall be
responsible for bringing any suit or action against Third Parties infringing the
Licensed Patent Rights or CIMYM/CIMAB's Arising Patents in the DAIICHI Field and
Territory at its sole expense.

    

    11.4   Infringement of
Third Party Rights.   If any warning letter or other
notice of infringement is received by a Party, or legal suit or other action is
brought against a Party alleging infringement of Third Party rights, the
receiving or sued Party shall promptly provide full details to the other Party,
and the Parties shall discuss the best way to respond.

    

    In the
case of the situation in Clauses 11.5(a), (b) and (c) of this Agreement,
CIMYM/CIMAB shall defend such suit or action and shall have the right to resolve
such matter by settlement or otherwise with such Third Party at CIMYM/CIMAB's
cost, provided that if any action or proposed settlement involves the making of
any statement, express or implied, concerning the validity of any Licensed
Patent Rights within the DAIICHI Field and Territory, the consent of DAIICHI
must be obtained before taking such action or making such settlement, such
consent not to be unreasonably withheld or delayed. CIMYM/CIMAB will request
DAIICHI's cooperation with the suit or legal action without DAIICHI joining as a
joint litigation party and DAIICHI may cooperate in the suit or action without
sharing the litigation cost.

    

     In
the case of situations other than in Clauses 11.5(a), (b) and (c) of this
Agreement, DAIICHI shall defend such suit or action and shall have the right to
resolve such matter by settlement or otherwise with such Third Party at
DAIICHI's cost.

    

    11.5   Third Party
Intellectual Property.   CIMYM/CIMAB shall be solely
responsible for obtaining and paying for any additional licenses and other
rights that may be required to enable DAIICHI or its Affiliates to commercialise
the Licensed Product in the Territory in the following situations. If as a
result of the use of the Licensed Intellectual Property:

    

    (a) the
Licensed Product is covered by a Third Party's patent claiming a composition of
matter, or

    

    (b) the
Licensed Product is covered by a Third Party's patent claiming a process for
manufacturing products, or

    

    (c) the
use of the Licensed Product is covered by a Third Party's patent claiming a
combination use of anticancer product with a radiation therapy or a
chemotherapeutic product.

    

    In
situations other than as set out in Clauses 11.5(a), (b) and (c), DAIICHI shall
be solely responsible for obtaining such licenses at its sole expense and for
obtaining and paying for any additional licenses and other rights that may be
required to enable DAI1CHI to commercialise the Licensed Products in the
Territory.

    

    The Third
Party's patents in the situations set out in Clauses 11.5(a), (b) and (c)
include, but are not limited to, the patents listed in Schedule
4, which are confirmed by the Parties as of the Commencement
Date.

    

    11.6   Product
Names.   DAIICHI may use its own trade mark for the Licensed
Product and shall be responsible for deciding the trade mark to be applied to
the Licensed Product in the Territory. DAIICHI will be responsible for applying
for any such trade mark in the Territory, at its sole cost. CIMYM will be
responsible for applying for an international, non-proprietary name ("INN") for
the Product at its sole cost. DAIICHI acknowledges that it has no objection to
the INN "NIMOTUZUMAB".

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    11.7   Licensed Patent
Validity.   DAIICHI agrees that it will not take any action, or
cause any other Person or other entity to take any action, seeking to invalidate
any Licensed Patent Rights.

    

    12   Representations,
Warranties and Liability

    

    12.1   Representations
and Warranties by CIMYM and CIMAB.   Each of the CIMYM and
CIMAB severally (and not jointly) represent and warrant that:

    

    (a) it
has all requisite corporate power and authority to enter into and perform its
obligations pursuant to this Agreement and to grant the sub-licenses herein
granted;

    

    (b) it
has not done, and will not do nor agree to do during the continuation of this
Agreement, any of the following things if to do so would be inconsistent with
the exercise by DAIICHI of the rights granted to it under this Agreement,
namely:

    

    (i) grant
or agree to rant any Third Party any rights in the Licensed Intellectual
Property in the DAIICHI Field and Territory; or

    

    (ii)
assign, mortgage, charge or otherwise transfer any of the Licensed Patent Rights
or rights to Arising Patents in the DAIICHI Field and Territory;

    

    (c) to
CIMYM and CIMAB's knowledge, no Third Party (other than CIMYM's licensor(s))
owns or claims any rights in the Licensed Patent Rights as of the Commencement
Date, other than those identified as possibilities in Schedule
4;

    

    (d) it is
a corporation incorporated and validly existing under the laws of its
jurisdiction of incorporation;

    

    (e) the
execution, delivery and performance of this Agreement by it have been duly and
validly authorized by all necessary corporate action on its part and this
Agreement is a legal, valid and binding obligation enforceable against it in
accordance with its terms, except as enforceability may be subject to
bankruptcy, insolvency and other laws affecting the rights or creditors
generally and except that equitable remedies may be granted only in the
discretion of a court of competent jurisdiction; and

    

    (f) to
its knowledge, without any additional investigation or inquiry, the Licensed
Know-how can be used as part of a Regulatory Application in the
Territory.

    

    12.2   Representations
and Warranties by CIMAB.   CIMAB represents and warrants
that:

    

    (a) it
has granted to CIMYM the rights set forth in Clause 2.1 hereof, which CIMYM is
sub-licensing to DAIICHI.

    

    12.3   Representations
and Warranties by DAIICHI.   DAIICHI represents, warrants
and undertakes that:

    

    (a) it
has sufficient financial and other resources to fulfil its obligations under
this Agreement;

    

    (b) it
has obtained all necessary authorisations from its supervisory board to use such
resources and fulfil such obligations;

    

    (c) it
has all requisite corporate power and authority to enter into and perform its
obligations pursuant to this Agreement;

    

    (d) it is
a corporation incorporated and validly existing under the laws of its
jurisdiction of incorporation;

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    (e) the
execution, delivery and performance of this Agreement by DAIICHI does not and
will not conflict with or result in a breach or violation of any of the terms or
provisions of, or constitute a default under (whether after notice or lapse of
time or both), any indenture, mortgage, deed of trust, loan agreement, license
agreement, lease or other agreement (written or oral) or instrument, including
any material contract, to which DAIICHI is a party or by which it is bound, or
to which its property or assets is subject; nor will such action conflict with
or result in any violation of the provisions of the articles of incorporation or
other documents, by-laws or resolutions of DAIICHI or any statute applicable to
DAIICHI or any order, rule or regulation of any court or governmental agency or
body having jurisdiction over DAIICHI or any of its properties;

    

    (f) the
execution, delivery and performance of this Agreement by DAIICHI have been duly
and validly authorized by all necessary corporate action on its pan and this
Agreement is a legal, valid and binding obligation enforceable against it in
accordance with its terms, except as enforceability may be subject to
bankruptcy, insolvency and other laws affecting the rights of creditors
generally and except that equitable remedies may be granted only in the
discretion of a court of competent jurisdiction;

    

    (g) to
its knowledge, as of the Commencement Date, the research, development,
importation, use and sale of the Licensed Product in the DAIICHI Field and
Territory does not infringe the rights of any Third Party, other than those
identified as possibilities in Schedule
4; and

    

    (h) it
shall comply in all material respects with all applicable laws in connection
with the performance of its obligations hereunder.

    

    12.4   No Other
Warranties.

    

    (a) Each
of DAIICHI, CIMYM and CIMAB acknowledges that, in entering into this Agreement,
it does not do so in reliance on any representation, warranty or other provision
except as expressly provided in this Agreement, and any conditions, warranties
or other terms implied by statute or common law are excluded from this Agreement
to the fullest extent permitted by law.

    

    (b)
Without limiting the scope of Clause 12.4(a), neither CIMYM or CIMAB give any
warranty or representation:

    

    (i) as to
the efficacy or usefulness of any of the Licensed Intellectual Property or
CIMYM's or CIMAB's Arising Intellectual Property; or

    

    (ii) that
any of the Licensed Patent Rights or CIMYM's or CIMAB's Arising Patents are or
will be valid or subsisting or in the case of a Regulatory Application will
proceed to grant; or

    

    (iii)
that the Licensed Know-how or Arising Intellectual Property or any other
information or materials communicated or provided by CIMYM to DAIICHI under or
in connection with this Agreement are sufficient for the research, development,
importation, use or sale of the Licensed Product in the DA IICHI

    Field and
Territory; or

    

    (iv) that
the research, development, importation, use or sale of the Licensed Product in
the DAIICHI Field and Territory will not infringe any rights of Third
Parties.

    

    12.5   Indemnity and
Insurance.

    

    (a)
DAIICHI shall indemnify and hold CIMYM and (except as otherwise provided in any
Supply Agreement) CIMAB and their respective Affiliates and their respective
officers, directors, employees, consultants, agents and representatives (the
"CIMYM/CIMAB
Indemnitees") harmless from and against all losses, liabilities, damages,
cost or expenses (including reasonable attorneys' fee and disbursements) ("Damages") incurred as a
result of any claim made or suit brought against or suffered by any of the
CIMYM/CIMAB lndemnitees arising out of (i) negligence, misconduct or breach by
DAIICHI of an agreement,
representation, warranty or covenant in this Agreement or (ii) the testing,
handling, storage, use, sale or other disposition of the Licensed Product by
DAIICHI or its Affiliate under this Agreement except to the extent that such
Damages are caused by or results from the failure of the Licensed Product that
is supplied to DAIICHI by CIMYM or CIMAB to meet the requirements as agreed upon
in the Supply Agreement.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    (b) CIMYM
and CIMAB shall severally and not jointly indemnify and hold DAIICHI and their
respective Affiliates and their respective officers, directors, employees,
consultants, agents and representatives (the "DAIICHI lndemnitees")
harmless from and against all Damages incurred as a result of any claim made or
suit brought against or suffered by any of the DAIICHI lndemnitees arising out
of (i) negligence, misconduct or breach by CIMYM/CIMAB of an agreement,
representation, warranty or covenant in this Agreement, (ii) CIMYM/CIMAB's
manufacture, use or sale of the Licensed Product to DAIICHI or (iii) the failure
of the Licensed Product that is supplied to DAIICHI by CIMYM or CIMAB to meet
the requirements as agreed upon in the Supply Agreements.

    

    (e) In
the event either CIMYM/CIMAB Indemnitees or DAIICHI Indemnitees (collectively
"Indemnitees") intend to
claim indemnification under this Clause 12.5, such lndemnitees shall: (i)
promptly notify the indemnifying Party in writing of any such claim with respect
to which the Indemnitees intend to claim such indemnification, (ii) give the
indemnifying Party sole control of the defence and/or settlement thereof, and
(iii) provide the indemnifying Party, at its expense, with reasonable assistance
and full information with respect to such claim. Notwithstanding the foregoing,
the indemnifying Party shall have no obligations for any claim if the
lndemnitees seeking indemnification makes any admission, settlement or other
communication regarding such claim without the prior written consent of the
indemnifying Party, which consent shall not be unreasonably
withheld.

    

    (d)
DAIICHI shall obtain appropriate product liability insurance with respect to
Licensed Products. At CIMYM's request, DAIICHI shall provide CIMYM with a
certificate of such insurance. Such product liability insurance shall be in
effect not later than the first administration of such a Licensed Product in
humans.

    

    13   Duration
and Termination

    

    13.1   Commencement and
Termination by Expiry.   This Agreement, and the rights
granted hereunder, shall come into effect on the Commencement Date and, unless
terminated earlier in accordance with this Clause 13.2, shall continue in full
force and effect for a period of ten (10) years after the first commercial sale
of the Licensed Product. Thereafter it will be automatically renewed for
subsequent periods of one (1) year, unless CIMYM or DAIICHI terminates by
written notice to the other Party at least one hundred and twenty (120) days
prior to the expiration of the initial term of this Agreement or renewed term
hereof.

    

    13.2   Early
Termination

    

    (a)
Without prejudice to any other right or remedy, either of CIMYM or DAIICHI may
terminate this Agreement at any time by notice in writing to the other Party
such notice to take effect as specified in the notice:

    

    (i) if
the other Party (which in the case of DAIICHI shall include any Affiliate of
DAIICHI) is in material breach of this Agreement and, in the case of a breach
capable of remedy within sixty (60) days, the breach is not remedied within
sixty (60) days of the other Party receiving notice specifying the breach and
requiring its remedy; or

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    (ii) if
the other Party becomes insolvent, or if an order is made or a resolution is
passed for the winding up of the other Party (other than voluntarily for the
purpose of solvent amalgamation or reconstruction), or if an administrator,
administrative receiver or receiver is appointed in respect of the whole or any
part of the other Party's assets or business, or if the other Party makes any
composition or proposal with its creditors or takes or suffers any similar or
analogous action in consequence of debt.

    

    (b)
Without prejudice to any other right or remedy, CIMYM and/or CIMAB may terminate
this Agreement at any time by notice in writing to DAIICHI, such notice to take
effect as specified in the notice:

    

    (i) if
the first contact with Regulatory Authorities for Phase I clinical trial for the
Licensed Product within the DAIICHI Field in the Territory has not commenced
within a period of ninety (90) days after the Commencement Date; or

    

    (ii) if
DAIICHI does not make decision to start pivotal study within six (6) months
after the completion of Phase II clinical trial; or

    

    (iii) if
a Change of Control takes place at DAIICHI, "Change of Control" as used
herein shall mean the acquisition of DAIICHI by a Third Party, a business
integration of DAHCHI with a Third Party by establishment of holding company, or
any other form of merger and acquisition of DAIICHI with a Third Party, in each
case as a result of which such Third Party shall directly or indirectly (i) own
fifty percent (50%) or more of the voting securities of DAIICHI, or (ii)
otherwise have the power to elect, replace or direct fifty percent (50%) or more
of the board of directors or comparable decision making body of DAIICHI;
or

    

    (iv) if
DAIICHI or any of its Affiliates commences legal proceedings, or assists any
Third Party to commence legal proceedings, to challenge the validity of any of
the Patents.

    

    Notwithstanding
the above (iii), it is understood that CIMYM and/or CIMAB shall not exercise the
above termination right by reason of DAIICHI's merger with Daiichi Sankyo Co.,
Ltd.

    

    (c) In
the event that DAIICHI considers, acting reasonably based on recommendations
from principal investigators or key opinion leaders involved in clinical studies
for the Licensed Product, it is seriously difficult to continue such clinical
studies due to lack of medical efficacy or safety of the Licensed Product,
DAIICHI shall promptly provide CIMYM with notice in writing of same. If the
Parties are unable to come to an agreement concerning continuation or cessation
of such clinical studies after good faith negotiation within ninety (90) days
after DAIICHI's notice, DAIICHI may terminate this Agreement effective in sixty
(60) days after DAIICHI's notice of its intention to terminate.

    

    (d)
DAIICHI may terminate this Agreement at any time by notice in writing to CIMYM,
in the event that (i) DAIICHI receives notice from the Japanese Regulatory
Authority that Regulatory Approval for the Licensed Product has been refused, or
(ii) after launch of the Licensed Product, DAIICHI receives notice from the
Japanese Regulatory Authority that the Licensed Product shall be withdrawn from
the market, and, in either case, after consultation between the Parties, in
DAIICHI's opinion, acting reasonably, there is no possibility of appealing such
refusal or withdrawal. DAIICHI undertakes to forward a copy of all relevant
notices to CIMYM promptly upon receipt.

    

    (e) The
Parties acknowledge and agree that DAIICHI's remedy for any breach by CIMYM or
CIMAB of their obligations under Clause 8 shall be as set out in any Supply
Agreement that CIMYM, CIMAB, DAIICHI and/or Daiichi's Affiliate may execute
pursuant to Clause 8.5. Accordingly, breach of Clause 8 shall not entitle any
Party to terminate this Agreement.

    

    13.3   Consequences of
Termination

    

    (a) Upon
termination or expiration of this Agreement for any reason:

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    (i) If
termination occurs after the first commercial sale of the Licensed Product in
the Territory, DAIICHI shall be entitled to sell, use or otherwise dispose of
any unsold or unused stocks of the Product for a period of six (6) months
following the date of termination following which it must destroy all such
Licensed Product; and if termination occurs prior to the first commercial sale
of the Licensed Product in the Territory, DAIICHI shall forthwith return all
such stocks of the Licensed Product and Licensed Know-how to CIMYM at DAIICHI's
sole expense;

    

    (ii)
subject to paragraph (i) above, DAIICHI shall no longer be sub-licensed to use
or otherwise exploit in any way, either directly or indirectly, any of the
Licensed Intellectual Property or CIMYM/CIMAB's Arising Intellectual
Property;

    

    (iii)
subject to paragraph (i) above, DAIICHI shall consent to the cancellation of any
formal sub-license granted to it, or of any registration of it in any register,
in relation to any of the Licensed Patent Rights;

    

    (iv) the
provisions of Clause 7, except Clause 7.1, shall survive termination and
continue in force for a period of five (5) years after the date of termination,
where applicable. For clarification, DAIICHI and its Affiliates shall have no
further right to use Licensed Know-how following termination or expiration of
this

    Agreement;

    

    (v) the
provisions of Clauses 9, 11.4, 11.5, 12, 13,3, and 14 are intended to survive
the termination or expiration of this Agreement and shall survive the
termination or expiration of this Agreement;

    

    (vi) any
and all rights and obligations accrued under this Agreement prior to termination
or expiration shall survive. Notwithstanding the foregoing, neither Party shall
be under any further Obligation to the other and CIMAB and CIMYM shall have the
right to issue licenses under the License Patent Rights to any Third Party
within DAIICHI's Field and Territory;

    

    (vii)
DAIICHI shall cease and shall cause any Third Party Manufacturer to cease
manufacture of the Licensed Product and destroy any materials used in the
production or manufacture of the Licensed Product within thirty (30) days;
and

     

    (viii) If
termination occurs prior to the approval of the Indication for the Licensed
Product in the Territory, DAIICHI shall provide the Licensed Product
continuously to patients who participated in the clinical trials conducted by
DAIICHI, if requested by such patients, and CIMAB/CIMYM shall supply to DAIICHI
the Licensed Product for such patients. The supply price for such Licensed
Product shall be US$1,000 per gram of TheraCIM h-R3 and be shared equally by the
Parties.

     

    (b)
Except in the case of a material breach by CIMYM as set out in Clause
13.2(a)(i), upon termination of this Agreement for any reason, at CIMYM’s
request, DAIICHI shall:

     

    (i)
transfer to CIMYM all clinical and other data relating to the development of the
Licensed Product;

     

    (ii) to
the extent possible, seek to have any Regulatory Approvals (including without
limitation product licenses and pricing approvals) and other permits and
applications transferred into the name of CIMYM or its nominee; and

     

    (iii)
grant CIMYM or its nominee the right to continue to use any product name that
had been applied to the Licensed Product prior to termination of this
Agreement.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    14    General

     

    14.1   Force
Majeure.

     

    (a) None
of the Parties shall be liable for any loss, injury, delay, damage or other
casualty suffered or incurred by any other Party due to strikes, lockouts,
labour disputes, riots, storms, fires, explosions, acts of God, war or any other
causes that are beyond the reasonable control of that Party (each, a “Force Majeure Event”), and
failure or delay by a Party in performance of any of its obligations under the
Agreement due to one or more Force Majeure Events shall not be considered a
breach of this Agreement.

     

    (b) The
Party whose performance is affected by a Force Majeure Event shall make
reasonable efforts to remedy the situation and remove, so far as possible,
and with reasonable dispatch, the cause of its inability to perform or comply,
provided however, that settlement of labour disputes, strikes, and lockouts
shall be wholly within the discretion of the Party involved.

     

    (c) If a
Force Majeure Event exists for more than ten (10) consecutive days, the Parties
shall meet to negotiate a mutually satisfactory solution to the problem.
Nothing herein shall relieve the Parties of their obligations to make
payments when due hereunder.

     

    14.2   Language and
Amendment.   This Agreement is made in the English
language and may only be amended in the English language in writing signed by
duly authorised representatives of the Parties. In the event of any conflict in
meaning between the English language version and any translation of this
Agreement, the English language version shall prevail. The provision of the
Licensed Intellectual Property and the Arising Intellectual Property shall be in
the English language.

    

    14.3   Assignment and
Third Party Rights

     

    (a)
Subject to Clause 14.3(b), no Party shall assign, mortgage, charge or otherwise
transfer any rights or obligations under this Agreement, nor any of the Patents
or rights under the Patents, without the prior written consent of the other
Parties.

    

    (b) With
the prior written consent of the other Parties, a Party may assign all its
rights and obligations under this Agreement together with its rights in the
Patents to any company to which it transfers all or substantially all of its
assets or business in the Field, provided that the assignee undertakes to be
bound by and perform the obligations of the assignor under this Agreement.
Notwithstanding the foregoing, no written consent will be required if a Party
transfers all or substantially all of its assets or business in the Field to a
wholly-owned Affiliate and the assignee undertakes to be bound by and perform
the obligations of the assignor under this Agreement.

    

    14.4   Waiver.  No
failure or delay on the part of either Party to exercise any right or remedy
under this Agreement shall be construed or operate as a waiver thereof, nor
shall any single or partial exercise of any right or remedy preclude the further
exercise of such right or remedy.

    

    14.5   Invalid
Clauses.  If any of the within terms, conditions or provisions
or the application of this Agreement shall at any time or to any extent, be
invalid or unenforceable at law such term, condition, or provisions shall be
severed from the remainder hereof which shall be affected thereby, and each and
every time and in each and every circumstance in which reference is made hereto
each term, covenant, condition and provision hereof shall be valid and be
enforced to the fullest extent permitted by law.

    

    14.6   No
Agency.  Neither Party shall act or describe itself as the
agent of the other, nor shall it make or represent that it has authority to make
any commitments on the other's behalf.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    14.7   Interpretation.      In
this Agreement:

    

    (a) the
headings are used for convenience only and shall not affect its
interpretation;

    

    (b)
references to persons shall include incorporated and unincorporated persons;
references to the singular include the plural and vice versa; and references to
the masculine include the feminine;

    

    (c)
references to Clauses and Schedules mean clauses of, and schedules to, this
Agreement;

    

    (d)
references to any Party shall include their permitted successors and permitted
assignees;

    

    (e)
references to any license shall mean, where the context requires, a
sub-license;

    

    (f) where
the word "including" is used, it shall be understood as meaning "including
without limitation"; and

    

    (g)
references to the grant of "exclusive" rights shall mean that the person
granting the rights shall neither grant the same rights (in the same Field and
Territory and in respect of the same Product) to any other person, nor exercise
those rights directly to the extent that and for as long as the Product is
within Valid Claims of unexpired Licensed Patent Rights or, to the extent that
the Product is protected by Licensed Know-how that have not become known and
available to the public.

    

    14.8   Notices

    

    (a) Any
notice to be given under this Agreement shall be in writing and shall be sent by
first class mail, air mail or by courier, or by fax (confirmed by first class
mail or air mail) to the address of the relevant Party set out at the head of
this Agreement, or to the relevant fax number set out below, or such other
address or fax number as that Party may from time to time notify to the other
Party in accordance with this Clause 14.8. The fax numbers of the Parties are as
follows:

    

    
      
        
          	
                  Party

                	  	
                  Fax Number

                
	
                  CIMYM: Chief Executive Officer

                	  	
                  001 905 629 4959

                
	
                  CIMAB: General Manager

                	  	
                  0053 7 273 3509

                
	
                  DAIICHI: General Manager of Licensing Department

                	
                    

                	
                  +81 3 3274 5704

                

        

      

    

    

    (b)
Notices sent as above shall be deemed to have been received three working days
after the day of posting (in the case of inland first class mail or national
courier), or seven (7) business days after the date of posting (in the case of
air mail or international courier), or on the next working day after
transmission (in the case of fax messages, but only if a transmission report is
generated by the sender's fax machine recording a message from the recipient's
fax machine, confirming that the fax was sent to the number indicated above and
confirming that all pages were successfully transmitted).

    

    14.9   Law, Dispute
Resolution.   The validity, construction and performance
of this Agreement shall be governed by the laws of England. Any dispute arising
out of or in connection with this Agreement shall first be discussed among the
Parties in good faith. If the Parties are unable or unwilling to resolve such
dispute within ninety (90) days of the dispute being referred to it, the dispute
shall be finally settled by arbitration in London, England pursuant to the Rules
of Arbitration of the International Chamber of Commerce, by which each Party
hereto agrees to be bound. Notwithstanding the foregoing, in the event of an
urgent issue that requires emergency action (such as a response to a Regulatory
Authority imposing a product recall, response to a product safety issue or other
similar urgent regulatory requirement), and there has been no timely resolution
using the process described above, DAIICHI will be entitled to make the decision
unilaterally. Nothing in this Agreement shall prevent a Party from seeking an
interim injunction or other equitable remedy in any court of competent
jurisdiction. Furthermore, in the event that a dispute involves a claim with
respect to the validity, enforceability, and/or alleged infringement of any of
the Licensed Patent Rights or Arising Patents owned by CIMYM or CIMAB,
CIMYM/CIMAB may have such matter resolved by a court of competent
jurisdiction.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    14.10   Further
Action.  Each Party agrees to execute, acknowledge and deliver
such further instruments, and do all further similar acts, as may be necessary
or appropriate to carry out the purposes and intent of this
Agreement.

    

    14.11   Announcements.  Neither
Party shall make any press or other public announcement concerning any aspect of
this Agreement, or make any use of the name of the other Party in connection
with or in consequence of this Agreement, without the prior written consent of
the other Party, except as may be required by law or by the rules of any stock
exchange on which either Party is listed. The Parties shall agree on a form of
press release for issue on signature of this Agreement.

    

    14.12   Entire
Agreement.  This Agreement, including its Schedules, sets out
the entire agreement between
the Parties relating to its subject matter and supersedes all prior oral or
written agreements, arrangements or understandings between them relating to such
subject matter. The Parties acknowledge that they are not relying on any
representation, agreement, term or condition that is not set out in this
Agreement. Nothing in this Agreement excludes liability for fraud.

    

    14.13   Third Party
Rights.  This Agreement is not made for the benefit of, nor
shall any of its provisions be enforceable by, any person other than the parties
to this Agreement and their respective successors and permitted
assignees.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    Agreed by the Parties through
their authorised signatories:

    

    For and
on behalf of CIMYM Biosciences
Inc.

    

    
      
        
          
            	
                      

                  	 
      	
                      

                  
	
                    David
      G.P. Allan

                  	 
      	
                    Sean
      E.L. Thompson

                  
	
                    CEO
      and Director

                  	 
      	
                    Director,
      Corporate Development

                  
	
                    Date

                  	
                      

                  	
                    Date

                  

          

        

      

    

    

    For an on
behalf of CIMAB
S.A.

    

    
      
        
          
            	
                      

                  	 	
                      

                  
	
                    Norkis
      Arteaga Morales

                  	 	
                    Normando
      Iznaga-Escobar

                  
	
                    General
      Manager

                  	 	
                    Head,
      Division of Business and Development

                  
	
                    Date

                  	 	
                    Date

                  

          

        

      

    

    

    For an on
behalf of

    DAIICHI
Pharmaceutical Co., Ltd.

    Kiyoshi
Morita

    President
& CEO

    Date

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    Schedule
I

    Licensed
Patent Rights

    

    The
patents and patent applications listed in this Schedule are, or may become,
relevant to this Agreement, but they also contain other rights not licensed
under this Agreement. Thus their inclusion here is limited to the extent if any
that they would protect the exploitation of the Licensed Product for
use

    within
the DAIICHI Field and in the Territory.

    

    PCT/CU2003/000012.

    

    Patent
Numbers:

    

    Japan:                                   
545689/04

    

    International
Filing Date: 22 October 2003 (22.10.2003)

    

    
      	
              Title:

            	
              METHOD
      OF OBTAINING CELL LINES IN A PROTEIN- FREE MEDIUM AND CELL LINES THUS
      OBTAINED

            

    

    

    
      	
              Applicant:

            	
              CENTRO
      DE INMUNOLOGIA MOLECULAR

            

    

    

    Schedule
2

    Licensed
Know-how and Confidential Information

    

    1. All
documentation that has been submitted by CIMYM or its Affiliates to the
Therapeutic Products Directorate of Health Canada in connection with an
application for an Investigational New Drug Submission for the Product in
Canada.

    

    2. All
documentation that has been submitted by CIMYM or its Affiliates to the United
States Food and Drug Administration in connection with an application for an
Investigational New Drug Submission for the Product in the USA.

    

    3. All
preclinical, clinical trial and manufacturing data generated by
CIMAB/CIMYM.

    

    4.
Summary and result of any data submitted to Korean FDA.

    

    5.
Summary and result of any data submitted to EMEA.

    

    6.
Summary and result of any data submitted to the Indian regulatory
authority.

    

    7.
Summary and result of any data submitted to the Chinese regulatory
authority.

    

    8. Any
other data submitted to any Regulatory Authority by current and future
sub-licensees of CIMYM of the Product, subject to any confidentiality
obligations to Third Parties if applicable.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    Schedule
3

    Initial
Development Plan

    

    Part
A: Initial Development Program

    

    DAIICHI
will conduct the following studies:

    

    Phase I
study: 2007.1Q - 2007.3Q

    

    
      	
               
      

            	
              ·

            	
              Glioma:
      adult: (Depend on Global Development
Program)

            

    

    Study
period: 2008. 1Q – 2009.2Q

    Registration:
2009. 4Q, Approval: 2010. 3Q

    
      	
               
      

            	
              ·

            	
              NSCLC:
      (Depend on Global Development
Program)

            

    

    Study
period: 2008 1Q - 2011. 1Q

    Registration:
2011. 3Q, Approval: 2012. 3Q

    
      	
               
      

            	
              ·

            	
              Esophageal:
      (Depend on Global Development
Program)

            

    

    Study
period: 2008. 1Q - 2011. 1Q

    Registration:
2011. 3Q, Approval: 2012. 3Q

    
      	
               
      

            	
              ·

            	
              Fourth
      indication to be decided

            

    

    

    Schedule
4

    Third
Party's Patents

    

    Japanese
Laid-Open Application No. 2002-114710

    
      	
              Title:

            	
              Treating
      Agent To Use Monoclonal Antibody Together With Antitumor
    Agent

            
	
              Assignee:

            	
              Rorer
      International Overseas Inc.

            
	
              Filed:

            	
              September
      14, 1989

            
	
              Status:

            	
              Final
      Rejection November 16, 2004, Appeal filed November 16,
  2004

            

    

    

    Japanese
Laid-Open Application No. 2005-47934

    
      	
              Title:

            	
              Treating
      Agent To Use Monoclonal Antibody Together With Antitumor
    Agent

            
	
              Assignee:

            	
              Rorer
      International Overseas Inc.

            
	
              Filed:

            	
              September
      14, 1989

            
	
              Status:

            	
              Pending

            

    

    

    Japanese
Laid-Open Application No.11-335297

    
      	
              Title:

            	
              Method
      of Treating Tumor Cells by Inhibiting Growth Factor Receptor
      Function

            
	
              Assignee:

            	
              Genentech
      Inc.

            
	
              Filed:

            	
              January
      5, 1989

            
	
              Status:

            	
              Pending

            

    

    

    Japanese
Laid-Open Application No. 2002-515511

    
      	
              Title:

            	
              Treatment
      of Human Turners With Radiation and Inhibitors of Growth Factor Receptor
      Tyrosine Kinases

            
	
              Assignee:

            	
              lmclone

            
	
              Filed:

            	
              May
      14, 1999

            
	
              Status:

            	
              Pending

            

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    Japanese
Laid-Open Application No.2003-520195

    
      	
              Title:

            	
              Treatment
      of Refractory Human Tumors with Epidermal Growth Factor
      Receptor

            
	  	Antagonists
	
              Assignee:

            	
              Imclone

            
	
              Filed:

            	
              May
      1, 2000

            
	
              Status:

            	
              Pending

            

    

    

    PCT/US01/46179
no application filed in Japan

    
      	
              Title:

            	
              Combination
      Radiation Therapy and Chemotherapy In Conjunction With Administration Of
      Growth Factor Receptor Antibody

            
	
              Assignee:

            	
              UAB
      Research Foundation

            
	
              Filed:

            	
              December
      7, 2001

            
	
              Status:

            	
              Pending

            

    

    

    Japanese
Laid-Open Application No. 2003-245091

    
      	
              Title:

            	
              Chimera
      Immunoglobulin Specific to P55TAC Protein of IL-2
  Receptor

            
	
              Assignee:

            	
              Protein
      Design Labs Inc.

            
	
              Filed:

            	
              December
      28, 1989

            
	
              Status:

            	
              Pending

            

    

    

    Japanese
Patent No. 2912618

    
      	
              Title:

            	
              Recombinant
      DNA Product And Its Production

            
	
              Assignee:

            	
              Medical
      Research Council

            
	
              Filed:

            	
              March
      27, 1987

            
	
              Status:

            	
              Issued

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}]]